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Summary
        Cysteine proteases modulate diverse biological functions through the degradation 
of various cellular proteins. In Plasmodium parasites, the causative agent of malaria, 
cysteine proteases are known to mediate cellular pathways vital for the initiation and 
development of a malaria infection in human host (i.e. host invasion, egression 
process, nutrient acquisition and propagation). Similarly, the human host also 
possesses a consortium of cysteine proteases. However, unlike the plasmodial cysteine 
proteases that promote the growth and development of the malaria parasite, the human 
cysteine proteases have been implicated in host defense mechanisms such as apoptosis 
that eliminate invading pathogens. Considering that both the plasmodial and human 
host cysteine proteases play  essential roles but with opposing functions, changes in the 
activities of these cysteine proteases can potentially impact on the survival of the 
malaria parasite in the human host. Recent studies have identified one inhibitor of 
cysteine proteases (ICP) in the murine model of malaria, Plasmodium berghei. The P. 
berghei ICP was found to inhibit both the plasmodial and human cysteine proteases 
implicated in haemoglobin degradation and host cell apoptosis, respectively. 
Interestingly, the P. berghei ICP subverted chemically induced cell death in human 
hepatoma cells in vitro, suggestive of its self-protective role during the exo-
erythrocytic stage of parasite development. Consequently, this sparks interests to 
investigate if the human malaria parasite, Plasmodium vivax, may  also disrupt host 
cell apoptosis through a similar mechanism observed in the murine model to promote 
their survival in the human host.
        In this study, a putative proteineacous inhibitor of cysteine proteases (ICP) was 
uncovered in P. vivax (PvICP) by genomic analysis. In silico analysis revealed that 
PvICP contains a cysteine protease inhibitor domain at  its C-terminus (PvICPc), 
prompting examination of its influence on the plasmodial cysteine proteases. Using 
solubly expressed recombinant proteins, PvICPc was found to inhibit the proteolytic 
activity of the plasmodial cysteine protease, vivapain 4 (Vx4). As Vx4 was postulated 
to be involved in the degradation of haemoglobin in the parasite for nutrient 
acquisition, the addition of PvICPc led to abrogation of the native haemoglobinase 
and auto-cleavage activities of Vx4. Interestingly, biocomputational analysis also 
revealed the presence of a putative signal peptide at the N-terminal of PvICP, 
suggestive of its potential secretion from P. vivax into the human host. Expression of 
PvICPc in human HepG2 cells revealed that PvICPc was able to confer protection to 
HepG2 cells against chemically  induced cell death in vitro. An inhibitor screen 
conducted against  all the 10 human caspases revealed that  PvICP did not exert any 
inhibitory effect on the activity of caspases, indicating that the anti-apoptotic activity 
observed in PvICP is independent of the caspase pathways. Instead, PvICP was found 
to inhibit the human cathepsins (a family  of cysteine proteases) that may be involved 
in cellular apoptosis. In summary, this study has identified a functional ICP from the 
Plasmodium parasites. that infects human and provided evidence on its regulation of 
both the plasmodial and human cysteine proteases. The inhibitory profile of PvICPc 
may pave the way for future studies to elucidate the pathways influenced by PvICP for 
apoptosis subversion, and potentially expand the understanding on how the malaria 
parasite operates to promote its survival in the human host. 
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 Plasmodium vivax is a neglected causative agent of human malaria, and is 
geographically, the most widespread species amongst the human Plasmodium 
parasites (Mueller et al., 2009). Once believed to inflict only  a benign form of the 
disease, it is now recognized that  severe morbidity and mortality can also arise from P. 
vivax infection (Manning et al., 2011; Price et al., 2009; Rogerson and Carter, 2008). 
However, past inattention in the area of P. vivax research and the absence of a robust 
protocol for culturing P. vivax parasites have led to a limited understanding of its 
biology  and the molecular mechanisms governing its cellular processes (Mueller et al., 
2009).
1.1 Cysteine proteases are important enzymes that influence parasite 
development
 Cysteine proteases are important enzymes that mediate important biological 
processes in a wide range of organisms, from bacteria to human. Likewise in the 
Plasmodium parasites, cysteine proteases have been shown to play crucial roles in 
mediating numerous biological responses required for it to complete its development. 
During the liver stage, plasmodial cysteine proteases from the papain family were 
found to facilitate the invasion process by cleaving the surface circumsporozoite 
proteins of Plasmodium sporozoites (Coppi et al., 2005). As the parasite progresses 
into the blood stage, cysteine proteases from the calpain and the papain families were 
also shown to facilitate important cellular processes such as cell cycle progression and 
haemoglobin degradation (Rosenthal et al., 1988; Russo et al., 2009). Disrupting the 
activities or expression of these cysteine proteases had been demonstrated to arrest the 
development and propagation of the Plasmodium parasite. Hence, proper regulation of 
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endogenous cysteine proteases (hereafter referred to as plasmodial cysteine proteases) 
is critical for the survival of the Plasmodium parasite. 
 Apart from endogenous cysteine proteases, the invading Plasmodium parasite 
is also likely  to encounter exogenous cysteine proteases (hereafter referred to as 
human host cysteine proteases) from the host cells. Several host cell cysteine 
proteases are known to mediate defense mechanisms against invading pathogens. For 
instance, host  cell cathepsins were reported to facilitate immunological responses, 
such as antigen presentation, and the proteolytic destruction of recognized pathogens 
(Blott and Griffiths, 2002; Hartmann and Lucius, 2003; Hsing and Rudensky, 2005; 
Luzio et al., 2007). The infected host cells may also activate cysteine proteases from 
the caspase family  to limit the spread of infection by  triggering apoptosis (Hacker et 
al., 1996). Successful execution of these host  defense mechanisms can undermine the 
survival of the Plasmodium parasite inside the infected host. Hence, mechanisms that 
allow the Plasmodium parasite to regulate the activities of host cell cysteine proteases 
are important to initiate and sustain a malaria infection. 
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1.2 Endogenous cysteine protease inhibitors in Plasmodium parasites
 Proteinaceous inhibitors of cysteine proteases (ICPs) have been described in 
Plasmodium falciparum, and the murine Plasmodium parasites, i.e. Plasmodium 
berghei and Plasmodium yoelii (Pandey et  al., 2006; Pei et al., 2013; Rennenberg et 
al., 2010). Biochemical characterization of recombinant P. falciparum ICP (PfICP) 
revealed its inhibitory activities against various families of cysteine proteases from 
both the Plasmodium parasites and the human host in fluorometric assays (Pandey et 
al., 2006). The principal targets of PfICP include falcipains 2 and 3, which are 
involved in the degradation of haemoglobin in P. falciparum. Consistent with this 
observation, P. yoelii ICP (PyICP) was found to interact with yoleipain 2, an 
orthologue of falcipain 2, during the erythrocytic stages as demonstrated by co-
immunoprecipitation experiments (Pei et al., 2013). 
 In P. berghei, the ICP (PbICP) expressed by the exoerythrocytic parasite was 
posttranslationally processed where the N-terminal domain was truncated 
(Rennenberg et al., 2010). This was similarly observed for PfICP and PyICP in a 
subsequent study performed by Pei et al. (2013) indicating a conserved 
posttranslational modification of plasmodial ICPs. The remaining C-terminal domain 
(PbICPc) was found to function as a potent inhibitor of papain-like cysteine proteases 
in vitro. Using PbICPc specific antibodies, PbICPc was detected in the 
parasitophorous vacuole as well as the cytoplasm of both the parasite and host cell 
during the liver stage. Interestingly, heterologous expression of PbICPc in HepG2, a 
human hepatoma cell line, was observed to protect the host cells from chemically 
induced apoptosis (Rennenberg et al., 2010). This indicated that PbICPc may function 
in the host cell cytoplasm to inactivate apoptotic mechanisms which in turn, promotes 
the survival of the parasite inside the infected hepatocyte. Since PfICP was previously 
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shown to inhibit human caspases 3 and 8, it was suggested that the suppression of host 
cell apoptosis by PbICPc occurred through the disruption of the human caspase 
cascade (Pandey et al., 2006; Rennenberg et al., 2010).
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1.3 Objectives of this project
 Considering the importance of cysteine protease regulation, it  was thus the aim 
of this project to investigate the presence and potential function(s) of a corresponding 
ICP in P. vivax Salvador I. Information gathered would be valuable in improving our 
understanding on how the cysteine proteases in P. vivax could be regulated. Since 
ICPs have been identified in other Plasmodium parasites, it was postulated here that 
the corresponding homologue may be present in P. vivax as well. To verify this 
hypothesis, this project set out to first identify  the putative P. vivax inhibitor of 
cysteine proteases (PvICP) and subsequently evaluate its inhibitory  profile against 
endogenous and exogenous cysteine proteases. 
Objective 1: Investigating the presence of a functional PvICP 
 Plasmodium parasites have been reported to express cysteine protease 
inhibitors that suppress the proteolytic activities of both endogenous and exogenous 
cysteine proteases. These inhibitors were also shown to play  important roles in 
regulating cysteine proteases during parasite invasion and development. In P. vivax, 
the presence of a corresponding homologue has so far not been reported. Hence, this 
study begins with an in silico approach to identify putative PvICP for subsequent 
heterologous expression and biochemical characterization.
Objective 2: Evaluating the activity of PvICP against a Plasmodium vivax 
cysteine protease
 Current evidence suggest that plasmodial ICPs interact with endogenous 
papain-like cysteine proteases in vivo (Pandey et al., 2006; Pei et al., 2013). However, 
the biological relevance of this interaction remains unexplored. To obtain information 
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on the potential function(s) of PvICP, the next objective of this study  was to obtain 
recombinant vivapain 4, a putative P. vivax cysteine protease, for subsequent 
biochemical characterization assays.
Objective 3: Examining PvICPc ability to suppress hepatocyte apoptosis and 
human cysteine protease activities
 Inhibition of human cysteine proteases by plasmodial ICPs has been suggested 
to disrupt host defense mechanisms against  the Plasmodium parasites in the infected 
host cells (Pandey  et al., 2006; Pei et al., 2013; Rennenberg et al., 2010). Interestingly, 
one such potential mechanisms disrupted by  plasmodial ICP was shown to be 
apoptosis in hepatocytes (Rennenberg et al., 2010). To evaluate if this function is also 
conserved in PvICP, it was the aim of this study to investigate:
(1) its ability to protect HepG2 cells from chemically-induced apoptosis and 








2.1 The global burden of Plasmodium vivax malaria
Human malaria is a debilitating, economically repressive and sometimes fatal 
disease that is endemic in many tropical and temperate countries. It was estimated that 
219 million clinical cases and 660 000 deaths occurred in 2011 globally (WHO, 
2012). Currently, five species of Plasmodium parasites are known to infect human, i.e. 
P. falciparum, P. vivax, Plasmodium malariae, Plasmodium ovalae and Plasmodium 
knowlesi, of which, P. vivax is the most widespread causative agent. 
2.1.1 Plasmodium vivax is a neglected causative agent of human malaria
Every  year, P. vivax threatens more than 2.8 billion people and was estimated 
to have caused more than 132 million clinical infections worldwide (Guerra et al., 
2010; Price et al., 2011). The global burden of P. vivax malaria was estimated to be 
approximately US$1.4 to 4 billion annually (Price et al., 2011). Its ability  to tolerate a 
broader temperature range ensured a wider geographical distribution and transmission, 
including sub-Arctic areas during the summer months (Shanks, 2012) (Figure 2.1). 
Despite these figures, P. vivax is often left in the shadows of P. falciparum and 
receives significantly less attention in research and funding. 
Estimates reported by Carlton et al. (2011) revealed that  across a span of 50 
years, 1960 to 2010, only 12% of the total malaria articles published had focused on P. 
vivax malaria. In addition, between 2007 and 2009, P. vivax research was only 
allocated a very small share of the total global malaria research funding, 
approximately 3% (PATH, 2011). In contrast, P. falciparum received a major share of 
approximately 45%. This huge disparity is largely due to the fact that P. falciparum is 
the most lethal Plasmodium parasite and the common perception is that P. vivax only 
causes a benign and self-limiting form of malaria (Price et al., 2007). While the 
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emphasis on P. falciparum is appropriate, the burden of P. vivax was severely 
underestimated since the latter accounts for almost half of total malaria cases annually. 
Furthermore, the notion that P. vivax can only cause a benign form of malaria is being 
challenged with increasing number of reports highlighting the development of severe 
clinical diseases as a result of P. vivax infection. 
Severe and fatal P. vivax malaria cases have been described in many  endemic 
countries, e.g. Malaysia, Indonesia and Papua New Guinea (Anstey et al., 2012). 
Anaemia, acute lung injury and respiratory distress, coma, acute kidney  injury, shock, 
multiple organ dysfunctions, and splenic rupture are some of the reported clinical 
manifestations associated with P. vivax infection (Anstey  et al., 2012). Clearly, it  is 







Figure 2.1 Comparing global regions suitable for P. vivax and P. falciparum 
transmission
The P. vivax parasites can complete their development in the mosquito at a lower 
temperature than P. falciparum. As a result, during the summer months, some 
temperate regions are able to support  P. vivax transmission and allow P. vivax malaria 
to reach a wider geographical distribution. To illustrate this, regions that (A) support 
the transmission of and (B) are endemic with P. vivax but not P. falciparum are 
indicated by black ovals. Maps were adapted from those published by  the Malaria 
Atlas Project (Gething et al., 2012; Hay and Snow, 2006).
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2.1.2 Plasmodium vivax possesses a complex life cycle
 P. vivax possesses a complex life cycle that alternates between a mosquito 
vector and a human host (Figure 2.2). Infection begins when the infected anopheline 
mosquito injects infectious sporozoites into the dermis of a susceptible individual. The 
sporozoites migrate and penetrate nearby  blood vessels where they would be carried 
to the liver sinusoid vessels. Inside the liver, they penetrate through the resident 
phagocytes, Küpffer cells, enter the Space of Disse, and invade the hepatocytes to 
initiate exoerythrocytic development (Baer et al., 2007b). 
 During the exoerythrocytic stage, P. vivax can choose to either undergo active 
development into merozoites or enter a state of inactivity as hypnozoites (Krotoski, 
1985). During active development, repeated mitotic replication in the infected 
hepatocytes produce thousands of reticulocytes-infectious merozoites over a period of 
about seven days (Galinski et al., 2013). In the murine model, yet to be shown in 
human malaria, mature merozoites are able to escape from the infected hepatocytes 
via a host cell membrane bound vesicle called the merosome (Baer et al., 2007a). 
These merosomes are proposed to protect the mature merozoites from the Küpffer 
cells which would otherwise recognize them as pathogens and initiate host defense 
mechanisms against them (Baer et al., 2007a). The merosomes subsequently rupture in 
the pulmonary microvasculature freeing the merozoites to invade the reticulocytes and 
initiate the symptomatic erythrocytic cell cycle, producing more merozoites (Baer et 
al., 2007a). 
 Alternate to the active development, P. vivax can form hypnozoites in the 
infected hepatocytes and lay dormant for a variable amount of time. They are usually 
triggered to initiate exoerythrocytic development after resolution of the primary 
infection resulting in a relapse. Although it  is not  known what factors trigger their 
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activation, it  was observed that tropical strains of P. vivax possess a shorter latency (up 
to six weeks) than those from the temperate region (up to a year). The longer latency 
was suggested to be an adaptive mechanism of P. vivax that allow it  to tide over 
climatic conditions that are inhospitable for the anopheline mosquito and transmission 
(Battle et al., 2012). The hypnozoites are currently undetectable and they form an 
important reservoir of P. vivax parasites in asymptomatic patients. Hence, it 
constitutes one of the biggest challenges in P. vivax control efforts (Mueller et  al., 
2009; Price et al., 2007).
 During the erythrocytic stage, a proportion of P. vivax parasites would deviate 
from this asexual cell cycle and produce gametes known as gametocytes. P. vivax 
gametocytes appear early, and may be present even before diagnosis or treatment of P. 
vivax malaria has begun (Douglas et al., 2010; McKenzie et al., 2002). These 
gametocytes serve as a bridge that allows the disease transmission from the human 
host to the anopheline mosquito (Sattabongkot et al., 2004). During a blood meal, the 
feeding mosquito picks up the gametocytes which develop  inside the gut of the 
mosquito, and form sporozoites completing its life cycle. Despite our understanding 
about the P. vivax life cycles, knowledge on cellular mechanisms that govern its 
development remain poorly understood.
15
Figure 2.2 Life cycle of the Plasmodium parasite
The infected anopheline mosquito (1) inoculates the Plasmodium sporozoites into the 
bloodstream of the human host. After being transported to the liver, they (2) invade 
the hepatocytes and either (3) lay  dormant as hypnozoites (P. vivax and P. ovalae) or 
(4) develop into merozoites. After the merozoites mature, the parasitophorous vacuole 
membrane is (5) broken down and the parasites are (6) packed in vesicles called 
merosomes. The merosomes are (7) transported into the bloodstream and (8) burst in 
the tight pulmonary microvasculature to release the merozoites. The merozoites (9) 
invade the red blood cells and either (10a) develop into more merozoites in the 
erythrocytic life cycle or (10a) deviate to produce gametocytes for transmission to the 
anopheline mosquito. During the erythrocytic life cycle, (11) large amount  of 
haemoglobin is degraded and the parasite food vacuole is characterized with the 
formation of hemozoin crystals. Unlike the exoerythrocytic life cycle, merozoites are 
released from the rupture of (12) parasitophorous vacuole membrane and (13) 
erythrocyte membrane.
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2.1.3 Current chemotherapy against Plasmodium vivax malaria
 Treatment for P. vivax malaria has changed little since the introduction of a 
combined therapy consisting of chloroquine and primaquine more than 50 years ago 
(Price et al., 2011). Chloroquine possesses potent schizonticidal activity  against 
sensitive P. vivax parasites. It is also cheap, widely available and familiar for most 
healthcare providers and hence, a popular choice of treatment for P. vivax malaria. 
However, its deployment in clinical settings is becoming increasingly difficult with 
reports of chloroquine-resistance P. vivax emerging in many endemic countries. In the 
latest World Malaria Report  2012, 23 countries have reported chloroquine treatment or 
prophylaxis failures, of which 10 countries have confirmed at least one case of 
chloroquine-resistant P. vivax (WHO, 2012). In cases of chloroquine resistance, 
artemisinin combined therapy (ACT) was recommended by WHO as the alternative 
(WHO, 2012). So far, ACT has proven to be very effective against chloroquine-
resistant P. vivax and no resistance has been reported. However, like chloroquine, 
ACT is unable to prevent relapse in P. vivax malaria and would require additional 
treatment with primaquine (Andrianaranjaka et al., 2013; Price et al., 2011).  
 Primaquine possesses hypnozoitocidal activity and is the only  licensed drug 
that can prevent the relapse P. vivax malaria (Galappaththy  et al., 2007). It is 
sometimes also given as a form of prophylaxis in P. falciparum malaria (Graves et al., 
2012). Primaquine treatment typically  last for 14 days with a daily  dose of either 0.25 
mg/kg or 0.5 mg/kg depending on the endemic area (WHO, 2010). Although it was 
shown to be effective in preventing relapse, two important problems are associated 
with the use of this drug: (1) haemolysis in glucose-6-phosphate dehydrogenase 
(G6PD) deficient patients; and (2) poor patient adherence to the 14-day primaquine 
regime (Baird and Rieckmann, 2003; Douglas et al., 2012). 
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 Primaquine is known to cause different degrees of haemolysis in patients who 
are G6PD deficient. In cases of severe deficiency, a single dose of primaquine is 
sufficient to result in mortality of the patient (Douglas et al., 2012). In areas endemic 
with P. vivax, it was estimated that 10-20% of the population possess G6PD 
deficiency (Brueckner et al., 1998). This problem is exacerbated by the continual 
absence of a reliable and rapid bedside test for G6PD deficiency (Price et al., 2011). 
Hence, in order to minimize the chance of undesired complications, primaquine was 
recommend by  WHO not to be given to children under the age of four and pregnant 
women, due to the unknown G6PD status of the fetus (Douglas et al., 2012; WHO, 
2012). In some healthcare providers, the administration of primaquine was completely 
omitted from the P. vivax malaria treatment (Price et al., 2011). In the absence of 
primaquine treatment, it is almost certain that a relapse will ensue and thus create 
additional burden to the affected patients. 
 The second problem with primaquine usage is its long treatment duration of 
two weeks. Poor adherence to the treatment regime not only results in relapses but 
would also pose a challenge in transmission control (Leslie et al., 2004). Trials has 
already began to examine the possibility  to shorten treatment period by  increasing the 
dose. So far, a seven day treatment with 1 mg/kg seems to be a promising alternative 
to the usual 14 days (Krudsood et  al., 2008). However, it is still considered long when 
compared to usual three days treatment  with chloroquine for schizonts. A three day 
treatment of primaquine at 3 mg/kg has been attempted but results did not reveal any 
added benefits and gastrointestinal discomfort  has been reported (Carmona-Fonseca 
and Maestre, 2009). 
 Considering the problems faced with primaquine, there has been some interest 
made to develop alternaive drug candidates. Currently, there are only two potential 
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hypnozoitocidal candidates, tafenoquine and NPC1161B (Schrader et al., 2012). Both 
tafenoquine and NPC1161B belong to the same drug class as primaquine, 8-
aminoquinoline. Tafenoquine is currently in Phase 2 clinical trials and similar to 
primaquine, it  can cause haemolysis in G6PD deficient individuals (Anthony et al., 
2012; Crockett and Kain, 2007). NPC1161B is in Phase 1 clinical trials and its toxicity 
against G6PD deficient individuals remains to be investigated (Douglas et al., 2012; 
Nanayakkara et al., 2008). With only two potential hypnozoitocidal candidates on the 
horizon, it appears that primaquine will remain an important drug against the relapse 
of P. vivax malaria for the next few years. Considering the propensity  of 8-
aminoquinoline to cause haemolysis in G6PD deficient individuals, development of a 
cheap, rapid and reliable test for G6PD deficiency appears to be an important priority 
in the combat against P. vivax relapse and transmission (Price et al., 2011). 
Undoubtedly, the development of new strategies against P. vivax hypnozoites is of 
even greater need. 
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2.2 Papain-like cysteine proteases in Plasmodium parasites and the human host
 Cysteine proteases are enzymes that  catalyze the hydrolysis of susceptible 
peptide bonds using the catalytic cysteine residue. These enzymes can hydrolyze their 
substrates within the polypeptide chain (endopeptidase activity) and/or at  the terminal 
end of the peptide (exopeptidase activity). In MEROPS (a peptidase and inhibitor 
database), there are currently 60 families of cysteine protease listed, of which cysteine 
proteases from the papain family  (C1) are amongst those that have been extensively 
studied.  
2.2.1 Structural features of papain-like cysteine proteases
 In human, lysosomal cathepsins are the important members of the papain-like 
cysteine protease family (Wiederanders et al., 2003). These proteases are synthesized 
as zymogens consisting of three parts: an N-terminal signal peptide, a prodomain and 
the mature domain. The N-terminal signal peptide facilitates the trafficking of the 
enzyme to the endoplasmic reticulum before being proteolytically removed (Chapman 
et al., 1997). A mannose-6-phosphate signal is then added to facilitate subsequent 
transport to the designated organelle, e.g. lysosome, via an appropriate receptor 
(Wiederanders et al., 2003). During the transport process, the prodomain interacts with 
the mature domain to assist with its proper folding and simultaneously inhibits it to 
prevent any inappropriate protease activity (Fox et al., 1992; Taylor et al., 1995; Zhu 
et al., 1989). These processes are usually  mediated by two highly conserved sequence 
motifs, the EFRNIN motif (EX2RX2(I/V)FX2NX3IX3N) and the GNFD motif 
(GXNXFXD) (Karrer et al., 1993; Vernet et al., 1995). Apart from these two motifs, 
the prodomains of C1 proteases are otherwise distinct in length and amino acid 
sequence similarities. These differences are plausibly important to ensure that only 
selective inhibition of the mature domain occurs (Turk et al., 2012). Although these 
20
features are conserved in most papain-like proteases, different structural features have 
been observed in falcipains (Figure 2.3) (Pandey and Dixit, 2012).
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2.2.2 Structural differences of plasmodial papain-like cysteine proteases
 Falcipains are important papain-like proteases from P. falciparum that form a 
family of four members, falcipains 1 (FP1), 2A (FP2A), 2B (FP2B) and 3 (FP3). They 
can be further divided into two subfamilies, FP1 and FP2/3, based on sequence, 
structural and functional similarities (Rosenthal, 2011). Like most papain-like 
proteases, members from the FP2/3 subfamily are synthesized as a zymogen 
consisting of three parts as described previously  (Figure 2.3). However, they do not 
utilize an N-terminal signal peptide for their trafficking. Instead, falcipains possess 
bipartite motifs that  mediate their translocation into the food vacuole, a lysosomal-like 
compartment in Plasmodium parasite (Subramanian et al., 2007). The bipartite motifs 
consist of three portions: an N-terminal cytosolic region, followed by the 
transmembrane and lumenal sections. Following expression, the transmembrane 
section directs the zymogen to the parasite plasma membrane via the endoplasmic 
reticulum. The zymogen is subsequently endocytosed and transported to the food 
vacuole, a process that requires both the cytosolic and lumenal portions. These 
differences in C1 protease trafficking are reflective of the distinct biology between the 
Plasmodium parasite and human host cell. 
 Although falcipains (hereafter referred to as members from the FP2/3 subfamily) 
lack the N-terminal signal peptide, the EFRNIN and GFND motifs are conserved in 
their prodomain (Pandey  et al., 2009). Similarly, these two motifs were found to 
inhibit the mature domain by masking its active site to prevent substrate entry. 
However, they  were apparently  not required to assist with the proper folding of the 
mature domain (Sijwali et al., 2002). A short 12 amino acid sequence folding domain 
that extends from the mature domain was instead found to be essential for falcipains 
to assume their correct tertiary  structures (Sijwali et al., 2002). This folding domain 
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appears to interact with the mature domain to stabilize it  for proper folding. 
Biocomputational analysis revealed that this folding domain is conserved in falcipain 
and its corresponding homologues from other Plasmodium species (Pandey and Dixit, 
2012; Wang et al., 2006). 
 Falcipains are known to exhibit  proteolytic activities against human 
haemoglobin and are regarded as the principal haemoglobinases of P. falciparum 
(Francis et al., 1996; Shenai and Rosenthal, 2002; Shenai et al., 2000; Sijwali et al., 
2001b). Interestingly, their interaction with haemoglobin requires a haemoglobin 
binding domain (HBD) which is unique to plamodial cysteine protease 
haemoglobinases (Wang et al., 2006). The haemoglobin binding domain consists of a 
14 amino acid long insertion in the mature domain, and it forms a β-hairpin that 
protrudes out of the enzyme. This β-hairpin is postulated to interact with haemoglobin 
via charged interactions and draws the substrate to the active site for hydrolysis (Wang 
et al., 2006).
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Figure 2.3 Comparing falcipains and human cathepsins revealed different 
functional domains and motifs 
Falcipains utilize different domains and motifs to facilitate transport to the food 
vacuole, inhibition of the mature domain, folding of the mature domains and 
interaction with haemoglobin substrate. This figure highlights these differences by 
comparing the general structural arrangement of falcipain with a human cathepsin. 
Legend: M-6-P - mannose-6-phosphate; * - the addition of M-6-P can occur either at 
the prodomain or mature domain; CTS - cytosolic sequence; TMS - transmembrane 
sequence; LMS - lumenal sequence; FD - folding domain and Hb - haemoglobin. The 
figure is not drawn to scale.
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2.2.3 Falcipains are principal haemoglobinases in Plasmodium falciparum
 Haemoglobin degradation is the best characterized function of falcipains and 
their corresponding homologues in other Plasmodium species. Amino acid residues 
released at the end of this degradation process are essential for the synthesis of 
parasitic proteins and the maintenance of osmotic stability  (Francis et al., 1997; Lew 
et al., 2003). Early  in the erythrocytic stage, the parasite begins the uptake of the 
haemoglobin substrate via cytosomal invaginations of erythrocyte cytoplasm at its 
periphery (Abu Bakar et al., 2010). The resultant endosomal vesicles are transported 
into the parasite where they would fuse to form a central food vacuole. During 
transport, these endosomes are acidified and glutathione present in the erythrocyte 
cytoplasm provides the reducing environment required for haemoglobinase activity 
(Shenai and Rosenthal, 2002). Current evidence suggest that falcipains initiate the 
degradation of the haemoglobin substrate, and release smaller protein fragments that 
are subsequently  hydrolyzed by other proteases (Figure 2.4) (Rosenthal, 2011). In 
addition, falcipains activate other haemoglobinases, i.e. plasmepsins, to augment the 
degradation process (Drew et al., 2008).  
 Apart from haemoglobin degradation, falcipains have also been found to be 
proteolytically active against erythrocyte membrane proteins and human kininogens in 
vitro (Cotrin et al., 2013; Dua et al., 2001; Hanspal et al., 2002). However, the 
biological significance of these findings remains to be explored.
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Figure 2.4 Falcipain 2A initiates the degradation process to release haeme and 
smaller protein fragments
Haemoglobin degradation is a cooperative process that involves proteases from 
different catalytic classes, cysteine – falcipains and dipeptidyl peptidase (DPP); 
aspartic – plasmepsins and histo-aspartic protease (HAP); metalloprotease – falcilysin 
(Goldberg, 2005). A recent study suggested that Falcipain 2A initiates the degradation 
process releasing smaller protein fragments and the toxic haeme byproduct (Chugh et 
al., 2013). The haeme is detoxified by  the haeme detoxification protein (HDP) while 
the protein fragments are further digested by the other haemoglobinases. The resultant 
dipeptides are further broken down to release single amino acids in the parasite 
cytoplasm plausibly by aminopeptidases.
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2.2.4 Papain-like cysteine proteases in Plasmodium vivax
 Prior this study, two papain-like cysteine proteases in P. vivax have been 
reported. Both of these proteases are corresponding homologues of falcipains and 
were annotated as vivapain 2 (Vx2) and vivapain 3 (Vx3) (Na et al., 2004). These 
proteases were similarly found to possess the bipartite motifs, folding domain and 
haemoglobinase binding domain via in silico analysis. Biochemical characterization 
assays performed using recombinant Vx2 and Vx3 revealed their proteolytic activities 
against human haemoglobin and erythrocyte membrane proteins in acidic and neutral 
pH conditions, respectively. However, their expression profile and localization in the 
P. vivax parasite were not investigated. Hence, it remains to be seen if Vx2 and Vx3 
play a role in the degradation of ingested haemoglobin in P. vivax.
27
2.2.5 Lysosomal cathepsins mediate diverse biological processes in human
 In contrast  to plasmodial papain-like cysteine proteases, our understanding of 
human cathepsins is more extensive. Currently, 11 cysteine cathepsins have been 
identified in the human genome i.e. cathepsins B, C, F, H, K, L, O, S V, X and W. 
These enzymes are known to play diverse roles such as host defensive mechanisms 
(Figures 2.5 and 2.6), angiogenesis, bone remodeling, cell differentiation and 
prohormone activation (Hartmann et al., 1997; Turk et al., 2000; Vasiljeva et al., 
2007). While commonly  found in lysosomal or endosomal compartments of the cells, 
cathepsins have also been detected in the nucleus, cytoplasm and plasma membrane to 
mediate different physiological processes. Not surprisingly, misregulation of these 
proteases are linked to clinical diseases such as neurological disorders, cardiovascular 
diseases and cancer (Joensuu et  al., 2007; Lutgens et al., 2007; Mohamed and Sloane, 
2006; Turk et al., 2004). Hence, there are interests to develop  inhibitors against human 
cathepsins as a form of chemotherapy (Cesen et al., 2012; Groth-Pedersen and 




Figure 2.5 Human cysteine proteases can mediate different host defense 
mechanisms
This figure was drawn to correlate the human cathepsins activities with their potential 
sites of action and biological processes against the Plasmodium parasites based on 
current literature. Biological processes mediated by the human cysteine proteases are 
illustrated around the circumference of the figure and assigned with unique roman 
numerals highlighted in yellow. The roman numerals were marked at different stages 
of the parasite cell cycle (center of the figure) to depict the potential sites of human 
cysteine protease actions. 
(i and ii) Cathepsins released by host cells can attack the invading parasites
Human cathepsins secreted by host  immune cells, e.g. macrophages, or released from 
fusogenic organelles in the infected host cells, e.g. lysosomes, can proteolytically 
attack the parasites at different stages of their development (Hartmann et al., 1997; 
Pandey et al., 2006). Furthermore, during egress, the Plasmodium merozoites are 
released into the host cytoplasm where they are likely  to be further exposed to the 
undesired actions of human cathepsins (Pandey et  al., 2006; Pei et  al., 2013; 
Rennenberg et al., 2010). 
(iii) Cathepsins and caspases can initiate cellular apoptosis to eliminate the 
parasites 
In addition, cathepsins can cooperate with caspases, cysteine proteases from C14 
family, to mediate apoptosis in the infected host cell to attenuate parasite 
development. While caspases are the direct mediators of apoptosis, cathepsins can 
promote the initiation of apoptosis through the activation of pro-apoptotic proteins 
(Figure 2.6) leading to eventual death of both the host  cell and the parasite residing 
inside (Droga-Mazovec et al., 2008).
(iv) Cathepsins can mediate immunological responses through MHC-II antigen 
presentation
Plasmodial proteins shed by  the parasite may be taken up by professional antigen 
presenting cells during endocytosis. Human cathepsins, e.g. L and S, are known to 
process these antigens and the invariant chains for major histocompatibility complex 
(MHC) class II antigen presentation (Beers et al., 2005; Hsing and Rudensky, 2005). 
(v) Human calpain-1 may attack the parasites during egress
The Plasmodium parasites co-opt the human calpain-1 to mediate the rupture of 
erythrocyte plasma membrane (Chandramohanadas et al., 2009). However, during the 
egress, the activated calpain-1 may act undesirably against the escaping merozoites 
(Pandey et al., 2006). 
Legend: CTS - human cathepsins; CSP - caspases; - initiator caspases; - 
executioner caspases; - extracellular cysteine proteases - human calpain-1; Mr - 
merosomes; - shed plasmodial proteins;  - cathepsin processed antigens; Y - 
antibodies;  - cytokines.
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Figure 2.6 Human cathepsins can initiate apoptosis via a mitochondria-
dependent pathway
The release of cathepsins into cell cytoplasm during lysosomal membrane 
destabilization can result in the initiation of apoptosis (Repnik et  al., 2012). 
Cathepsins in the cytoplasm degrade the anti-apoptotic proteins, i.e. B cell lymphoma 
2 (Bcl-2) members and X-linked inhibitor of apoptosis protein (XIAP), and activate 
pro-apoptotic protein, i.e. BH3 interacting domain protein (Bid), to promote apoptosis 
(Cirman et al., 2004; Droga-Mazovec et al., 2008). Degradation of Bcl-2 proteins 
releases the pro-apoptotic Bcl-2 associated X protein (Bax), Bcl-1 antagonist (Bak) 
and tBid to induce the permeabilization of mitochondria outer membrane (Chipuk et 
al., 2010). This results in the release of cytochrome C which associates with apoptotic 
protease-activating factor 1 (apaf-1) to activate the initiator caspase 9 and in turn the 
caspase signaling cascade (Tait and Green, 2010). The activation of downstream 
executioner caspases 3, 6 and 7, eventually leads to apoptosis in the cell. 
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2.3 Regulation of papain-like cysteine proteases by endogenous protein inhibitors
 Endogenous protein inhibitors are important  regulators of mature papain-like 
cysteine proteases in many eukaryotic organisms (Turk et al., 2012). These cysteine 
protease inhibitors are usually competitive inhibitors that bind reversibly and tightly 
over the active site of their targeted proteases to prevent substrate interactions (Turk et 
al., 2012). Their physiological functions divide them into two main categories, 
emergency inhibitors (e.g. cystatins) and regulatory inhibitors (e.g. prodomains of 
papain-like cysteine proteases) (Turk et al., 2002). Emergency  inhibitors function 
mainly to suppress the activities of cysteine proteases that escaped from their native 
localization, e.g. lysosome, to prevent cellular damages or cysteine proteases from 
invading pathogens. In contrast, regulatory inhibitors work to modulate the activity of 
the proteases and release them to act on their substrates at the appropriate time. 
2.3.1 Cystatins are common inhibitors of papain-like cysteine proteases
Cystatins are classical inhibitors of papain-like cysteine proteases and are 
commonly found in eukaryotes (Turk et al., 2012). They possess diverse functions and 
form a superfamily of inhibitors that is further divided based on the presence or 
absence of disulphide bonds and the number of cystatin-like domains present in the 
inhibitor (Ochieng and Chaudhuri, 2010; Turk et al., 2012). Cystatin-like domains 
generally  consist  of a five-turn α-helix and a five-stranded β-pleated sheet and are 
usually  thermostable (Bode et  al., 1988; Lenney et  al., 1979; Stubbs et al., 1990). 
Interaction with the target proteases is mediated by a tripartite consisting of the amino 
terminus and two β–hairpin loops. They  form hydrophobic wedge-like structures that 
insert complementarily into the active-site cleft of the targeted protease preventing 
substrates from entering the same site (Bode et al., 1988; Stubbs et al., 1990). 
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Currently, cystatins are classified into three subfamilies and assigned as I25A, 
I25B or I25C in MEROPS (Ochieng and Chaudhuri, 2010). Type 1 cystatin, subfamily 
I25A, is small protein molecule consisting of ~100 amino acid residues and possesses 
one cystatin-like domain. It  is found mainly inside the cell and does not possess any 
disulphide bonds (Turk and Bode, 1991). Generally it functions to regulate the 
turnover of proteins inside the cell. In Schistosoma mansoni, a human parasite, type 1 
cystatin was reported to regulate the haemoglobin degradation process (Turk et al., 
2012; Wasilewski et al., 1996). 
Type 2 cystatin, subfamily I25B, is similar to type 1 cystatin except that it is a 
secretory protein that possesses a signal peptide and two highly conserved disulphide 
bonds. However, it  is also small, ~115 amino acid residues long, and possesses only 
one cystatin-like domain. As expected, type 2 cystatins are responsible for regulating 
protein turnover outside the cells. Interestingly, this cysteine protease inhibitor has 
been reported to facilitate the down regulation of immune-responses against parasitic 
nematodes through the inhibition of host cysteine proteases such as cathepsins L and S 
(Kotsyfakis et al., 2006; Manoury et al., 2001; Murray et al., 2005; Schnoeller et  al., 
2008). 
Type 3 cystatin, I25C subfamily, is a multidomain and usually, mutifunctional 
protein that possesses more than one cystatin-like domain, and disulphide linkages are 
usually  present. However, the cystatin domains do not necessary  exhibit inhibitory 
activity against cysteine proteases. For example, kininogen possesses three cystatin-
like domains but only the second and third domains are known to exhibit  inhibitory 
activities (Salvesen et  al., 1986). Kininogen is a well-characterized member of type 3 
cystatin and is known to be implicated in numerous biological processes such as blood 
coagulation in human (Kaplan and Silverberg, 1987). 
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2.3.2 Chagasin is a unique inhibitor of cysteine proteases
Although cystatins have been extensively  studied, the corresponding 
homologues were not found in protozoan parasites. For a long time, it was postulated 
that cysteine protease inhibitors are absent in these parasites until the experimental 
identification of chagasin (Monteiro et al., 2001). Chagasin is a cysteine protease 
inhibitor uncovered in Trypanosoma cruzi and is the founding member of protozoan 
cysteine protease inhibitors, family I42 in MEROPS database. Exploiting the 
thermostable property  of cysteine protease inhibitors, Monteiro et al. (2001) isolated 
the thermo-resistant  chagasin bound to cruzipain, an endogenous papain-like protease, 
from the heat-denatured cell lysate of T. cruzi parasite. This protozoan cysteine 
protease inhibitor was not found to possess any primary sequence homology with 
previously  characterized cystatins despite having similar biochemical characteristics, 
such as potent inhibitory activity against papain-like cysteine proteases. 
Structural studies performed using nuclear magnetic resonance and X-ray 
crystallography  techniques, revealed a β-strand rich structure of chagasin and more 
importantly, three loops that are responsible for interaction with its target cysteine 
protease (Figueiredo da Silva et al., 2007; Ljunggren et al., 2007; Salmon et  al., 2006; 
Wang et al., 2007). This mechanism of interaction was reminiscent of that in cystatin 
suggesting a similar mode of protease interaction between the two otherwise different 
proteins (Figure 2.7). Using chagasin as a template, cysteine proteases inhibitors were 
subsequently  identified in other protozoan parasites such as Cryptosporidium parvum, 
Entamoeba histolytica and Plasmodium falciparum (Kang et al., 2012; Pandey et al., 
2006; Riekenberg et al., 2005). These parasite cysteine protease inhibitors possess 
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diverse functions regulating endogenous and/or host cysteine proteases to facilitate 
parasite survival and invasion (Santos et al., 2006).
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2.3.3 Inhibitors of cysteine proteases in Plasmodium parasites
Cysteine proteases from both the Plasmodium parasites and human host 
mediate important biological functions that influence parasite development and 
survival. However, information on how the parasite regulates activities to facilitate its 
life cycle inside the human host remains limited. Hence, there is an interest to 
investigate if the Plasmodium parasites possess cysteine protease inhibitor(s) that may 
fulfill this physiological role. Using the chagasin amino acid sequence as a search 
template in BLAST, a putative ICP was identified in P. falciparum (Pandey et al., 
2006). The discovery  of PfICP led to subsequent identification and characterization of 
the corresponding homologues in P. berghei and P. yoelii (Pei et al., 2013; Rennenberg 
et al., 2010). 
2.3.4 Structural differences between plasmodial ICP and chagasin
Plasmodial ICPs possess two domains, a chagasin-like domain at the C-
terminal and an N-terminal extension of unknown function. Although the C-terminal 
domain of plasmodial ICP exhibited limited sequence homology to chagasin, it 
possesses a tertiary  structure similar to that of chagasin (Hansen et  al., 2011; Pandey 
et al., 2006). X-ray crystallographic study of PbICPc revealed an immunoglobulin-like 
tertiary  structure consisting of an alpha helix and eight beta strands that are arranged 
as two antiparallel sheets (Hansen et al., 2011). Similar to chagasin, PbICP interacted 
with the target protease at its catalytic cleft via wedge-like structures, loop 2, loop 4 
and loop  6. However, the amino acid sequences on the loop 2 and loop 4 PbICPc do 
not bear any sequence similarities with that of chagasin. Furthermore, PbICP was 
found to further interact with the target protease outside the catalytic cleft using an 
additional loop, loop 0, enhancing the affinity of PbICP for the interacting protease. 
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Taking these differences into account, plasmodial ICPs were thus classified under a 
new family of cysteine proteases, I71, in MEROPS database.
Figure 2.7 Cysteine protease inhibitors interact with the target proteases via 
similar mechanisms
Despite the absence of any obvious sequence homology, interaction between cysteine 
proteases and cysteine protease inhibitors from different families remains largely 
similar via three or more wedge-like shaped structures (yellow). (A) Human cystatin 
A:cathepsin L protein complex (PDB ID: 3KSE); (B) chagasin:cathepsin L (human) 
protein complex (PDB ID:2NQD; Ljunggren et al. 2007); and (C) PbICPc:falcipain2 
protein complex (PDB ID:3pnr; Hansen et al. 2011)
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2.3.5 Plasmodial ICPs are potent inhibitors of papain-like cysteine proteases
Biochemical characterization of plasmodial ICPs unveiled their potent 
inhibitory activities against papain-like cysteine proteases from both the parasite and 
the human host (Hansen et al., 2011; Pandey  et al., 2006; Rennenberg et al., 2010). In 
the case of PfICP, it  was additionally reported to inhibit cysteine proteases from the 
human calpain and caspase families (Pandey et al., 2006). However, unlike other 
protozoan ICPs, plasmodial ICPs are inactive against  cysteine proteases that possess 
exopeptidase activities, e.g. human cathepsin B. Nonetheless, their ability to target 
both parasite and host cysteine proteases for inhibition has ignited interest to further 
investigate their biological significance during the parasite exoerythrocytic and 
erythrocytic stages. Results obtained suggest that they facilitate host  cell invasion and 
protect the parasites from actions of host  cysteine proteases (Pandey et al., 2006; 
Rennenberg et al., 2010). 
2.3.6 Plasmodium parasite invasion requires plasmodial ICPs
PbICP was found to be constantly secreted by  the P. berghei sporozoites 
during migration and hepatocyte invasion (Rennenberg et al., 2010). When the 
migrating sporozoites were treated with anti-PbICP antiserum, the parasites were 
found to be trapped in the migratory phase and were unable to invade the hepatocytes. 
Invasion of hepatocytes has been reported to be initiated via the timely cleavage of a 
parasite surface protein, circumsporozoite protein, by a cysteine protease of parasite 
origin (Coppi et al., 2005). Hence, it was postulated that attenuation of PbICP by the 
antiserum disrupted the assurance that  the cleavage of CSP occurs in a timely and 
well-orchestrated manner by the intended cysteine protease (Rennenberg et al., 2010). 
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Interestingly, the involvement of plasmodial ICP during erythrocyte invasion was also 
described in P. falciparum (Pandey et al., 2006). 
P. falciparum constantly secretes PfICP during its migration (Pandey et al., 
2006). To investigate if it was essential for parasite invasion, the merozoites were 
treated with anti-PfICP antibodies that attenuate its inhibitory  activities. The treatment 
was found to impede erythrocyte invasion by the merozoites suggesting that the 
inhibition of cysteine proteases is also essential for parasite invasion during the 
erythrocytic stage. However, unlike the situation during the exoerythrocytic stage, the 
invasion of erythrocytes was reported to be mediated by serine proteases (Harris et al., 
2005; O'Donnell and Blackman, 2005). Hence, the role of PfICP here appears to help 
limit undesired activities of cysteine proteases at the site of invasion, thereby allowing 
selective hydrolysis by the intended proteases to take place (Pandey et al., 2006).
2.3.7 Suppression of host cell apoptosis and host defense mechanisms by 
plasmodial ICP
Apart from their implications during the invasion of host cells, plasmodial 
ICPs have also been proposed to play important roles protecting the parasites from 
undesired activities of cysteine proteases during development and egress. Presence of 
plasmodial ICP has been detected in the parasite cytoplasm, parasitophorous vacuole 
and host cell cytoplasm at different stages of parasite development (Pandey et al., 
2006; Pei et al., 2013; Rennenberg et  al., 2010). Inside the parasite cytoplasm, they 
were suggested to protect the parasite against endogenous cysteine protease 
haemoglobinases that may be released during schizont rupture prior to merozoite 
egress (Pandey et al., 2006). In addition, they  may inhibit host cell cysteine proteases 
that can attack the parasites growing in the parasitophorous vacuole via fusogenic 
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organelles or when the parasites are temporarily  present in the host cytoplasm prior 
egress (Pandey et al., 2006; Pei et al., 2013; Rennenberg et al., 2010). Of these 
protective functions proposed, an interesting mechanism was reported by Rennenberg 
et al. (2010). PbICP was demonstrated to suppress hepatocyte apoptosis, supporting 
the exoerythrocytic development and parasite egress during P. berghei infection. 
Apoptosis is a highly  specific and efficient defense system of the host cell for 
eliminating intracellular pathogens upon detection (van de Sand et al., 2005). To 
ensure survival, intracellular pathogens, such as viruses and protozoan parasites, have 
to develop  strategies to counteract host cell apoptosis (Hacker et  al., 1996; Heussler et 
al., 2001). In Plasmodium, infection with P. berghei sporozoites was found to confer 
resistance of the infected host cell against  chemically induced apoptosis (van de Sand 
et al., 2005). It was proposed that the subversion of host apoptosis facilitates parasite 
development and subsequent egress via the merosomes (Sturm et al., 2006). Since 
cysteine proteases from the papain and caspase families are known mediators of 
apoptosis, their inhibition by  plasmodial ICP offers an attractive mechanism to 
account for the inhibition of host cell apoptosis (Chowdhury et al., 2008; Rennenberg 
et al., 2010; Stoka et al., 2007). Consistent with this postulation, presence of PbICPc 
was detected in the infected hepatocyte cytoplasm during the early  stages of 
exoerythrocytic development (Rennenberg et al., 2010). Further investigation revealed 
that heterologous expression of PbICPc was sufficient  to protect HepG2 cells (human 
hepatoma cell line) from chemically induced apoptosis. These results were thus 
supportive of the theory that plasmodial ICP suppresses host cell apoptosis via the 
inhibition of host pro-apoptotic cysteine proteases. 
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2.3.8 Plasmodial ICP is an essential protein for the Plasmodium parasite
Functional analysis of plasmodial ICPs has put forward convincing evidence 
to show their importance during parasite development (Pandey et al., 2006; 
Rennenberg et al., 2010). This is substantiated when attempts to produce PbICP and 
PyICP knockouts via several independent strategies were unsuccessful (Pei et al., 
2013; Rennenberg et al., 2010). Hence, it suggests that strategies developed to disrupt 
the functionality of these proteins may pave the way  for antimalarial intervention. 
Indeed, a hint of this possibility  came when mice immunized with plasmid DNA and 
vaccinia virus expressing PyICP were found to protect against the development of 
murine malaria (Limbach et al., 2011).
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Figure 2.8 Putative roles of plasmodial ICP during the Plasmodium parasite life 
cycle
This figure was drawn to correlate the plasmodial ICP inhibitory  profile with their 
potential sites of actions and physiological consequence based on current reports. 
Inhibition of different proteases by  plasmodial ICP illustrated around the 
circumference of the figure and assigned with unique roman numerals highlighted in 
yellow. The roman numerals were marked at  different stages of the parasite cell cycle 
(center of the figure) to depict the potential sites of plasmodial ICP actions. 
(i & ii) Plasmodial ICP inhibits cathepsins released by the host cells to protect the 
invading Plasmodium parasites
Human cathepsins released by the host cells can proteolytically attack the parasites at 
different stages of their development. Secretion of plasmodial ICPs during migration 
into the extracellular matrix, intracellular development into the parasitophorous 
vacuole or host  cytoplasm, and release during parasitophorous membrane breakdown 
suggest that they may function to counter the activities of human cathepsins and thus 
protect the Plasmodium parasites.
(iii) Inhibition of human cathepsins and caspases can prevent initiation of 
apoptosis in the infected host cell 
Cathepsins and caspases can initiate host cell apoptosis leading to eventual death of 
both the host cell and the parasite hidden inside. Plasmodial ICPs localized into the 
cytoplasm of host cells may inhibit these proteases to subvert the cellular apoptotic 
mechanism. 
(iv) Secretion of plasmodial ICPs during parasite invasion may help to ensure 
timely processing of parasite surface proteins
Presence of extracellular cysteine proteases, from both parasite and host, can lead to 
unspecific and/or untimely processing of parasite surface proteins resulting in 
invasion failures. Secreted plasmodial ICPs may function to inhibit these unspecific 
activities. 
(vi) Release of plasmodial ICPs during egress may protect the parasite from 
endogenous cysteine protease haemoglobinases
Plasmodial cysteine protease haemoglobinases, e.g. falcipains, are expressed during 
the erythrocytic stage to degrade the ingested haemoglobin substrate. However, during 
egress in the erythrocytic stages, schizont rupture may inevitably  result in their release 
from the confines of the food vacuole and uncontrolled activities against the escaping 
merozoites. Release of plasmodial ICP during the egress can inhibit their activities to 
protect the escaping merozoites.
(v) Plasmodial ICPs may inhibit human calpain-1 to protect the escaping 
parasites 
During egress, activated human calpain-1 may  proteolytically attack the escaping 
merozoites. However, secretion of plasmodial ICP by the merozoites may act to 
inhibit the activities of calpain-1 protecting the parasites during egress. 
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Legend: - plasmodial ICP; CTS - human cathepsins; CSP - caspases; - initiator 
caspases; - executioner caspases; - extracellular cysteine proteases - human 
calpain-1; Mr - merosomes; dotted lines indicate the biological processes that may  be 






3.1 Cultivation and maintenance of Escherichia coli
 Esherichia coli TOP10 (Invitrogen) and BL21 (DE3) cells were used to 
propagate plasmids and heterologously express proteins of interest, respectively. 
Sterile Luria-Bertani (LB) broth consisting of 1% (w/v) tryptone, 0.5% (w/v) yeast 
extract and 1% (w/v) NaCl, or LB agar which contained an additional 1.5% (w/v) agar 
were used to culture both bacterial strains at 37oC. When necessary, antibiotics, i.e. 
kanamycin (50 µg/ml) or ampicillin (100 µg/ml), were supplemented in the culture 
media to select for cells harboring the plasmid of interest. Cryopreservation of E. coli 
stocks was performed with the addition of sterile glycerol to 10% (w/v) at -80oC.
3.2 Preparation of electro-competent Escherichia coli cells
A single colony  of E. coli cells was picked from a streaked LB agar plate and 
inoculated into 5 ml of sterile LB broth. The liquid culture was incubated overnight at 
37oC and agitated by a rotary  shaker set  at  220 rpm. Following this, 1 ml of the 
overnight bacterial culture was inoculated into fresh 100 ml LB broth and allowed to 
grow until the mid-log phase (OD600 = 0.6-0.8). The culture was then chilled on ice 
for 30 min before transferring into sterile centrifuge tube. The cells were then pelleted 
via centrifugation at 3000 rpm for 10 min at 4oC, and washed twice with 50 ml of ice-
cold 10% (w/v) glycerol. In between each wash, the pellet was gently resuspended 
using a 10 ml sterile pipette. After the final wash, the cell pellet was gently 
resuspended in 0.5 ml of ice-cold 10% glycerol and aliquots of 40 µl were pipetted 
into separate sterile microfuge tubes. The prepared cells were either used immediately 
for electro-transformation or stored frozen at -80°C for subsequent use.
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3.3 Transformation of electro-competent Escherichia coli cells
To transform the electro-competent E. coli cells, 1 - 5 µl of plasmid or ligation 
mixture was first added to the thawed E. coli cells using a sterile pipette. The resultant 
mix was then transferred into an ice-cold electroporation cuvette with an electrode gap 
of 0.2 cm and incubated on ice for 45s (Bio-Rad). After which, the cuvette was loaded 
into the Bio-Rad Gene Pulser® and a short electric pulse of 2.5 kV was rendered 
across the cuvette. After electroporation, the cuvette was transferred back on ice for 45 
s before the addition of 1 ml of sterile LB broth. Following a gentle resuspension, the 
transformed cells were pipetted into sterile microfuge tubes, and incubated at 37°C for 
1 h with agitation at  220 rpm to allow recovery. After the recovery period, the cells 
were pelleted at  3000 rpm, and plated on LB agar supplemented with the relevant 
antibiotics to select for transformants. The plates were incubated overnight at 37oC, 
and well-isolated colonies were picked to screen for the desired plasmid the following 
day. 
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3.4 Cultivation and maintenance of HepG2 cells
The HepG2 cell line were purchased from ATCC (USA) and maintained in T25 
flasks (Iwaki, Japan) using Dulbecco's Modified Eagle's Medium (DMEM; Sigma, 
USA) supplemented with 10% (v/v) fetal calf serum (FCS; Hyclone, USA). The cell 
culture was incubated at 37°C and 5% CO2 with the flask cap loosened for ventilation. 
When the confluence reached ~90%, the cells were harvested and seeded into either 
fresh flasks or 24-well plates for continual culture or transfection. To harvest cells, the 
culture was first washed twice using sterile phosphate buffered saline (PBS, pH 7.5) 
and treated with 1 mL of 1X cell culture grade trypsin with 3 min incubation at 37°C 
in the CO2 incubator. The culture flask was gently  tapped to dislodge the cells and the 
activity of trypsin was quenched with the addition of 9 ml of fresh culture medium. 
The mixture was collected in a 15 mL falcon tube and the cells were pelleted by 
centrifugation at 1500 rpm for 2 min at 20°C. The supernatant was removed and the 
fresh culture medium was used to re-suspend the cells. A haemacytometer was used to 
quantitate the concentration of cells and approximately  1 million cells were split  into 
fresh culture flasks. 
To prepare frozen stock, the harvested cells were re-suspended with 1.5 ml of 
freezing medium, consisting of DMEM supplemented with 10% (v/v) FCS and 10% 
(v/v) DMSO (dimethyl sulfoxide; Sigma, USA). Following this, the cells were 
pipetted into cryo-vials (Nunc, Denmark) and floated in isopropanol, before being 
transferred into a -80°C freezer. To revive the frozen stocks, cryo-vials were incubated 
in a 37°C water bath and the thawed contents were quickly  transferred into 15 ml 
falcon tubes containing 10 ml of culture medium. The cells were pelleted by 
centrifugation and fresh culture medium was used for resuspension of the cells. The 
contents were transferred into a sterile T25 flask and incubated at 37°C with 5% CO2.
48
3.5 Transfecting of HepG2 cells
To obtain sufficient endotoxin-free plasmids for HepG2 cells transfection, 
cultures of E. coli TOP 10 cells harboring pXJ40/PvICPc or pXJ40 plasmids (a gift 
from Professor Edward Manser, A*STAR, Singapore, (Manser et al., 1997)) were 
cultured overnight at 37ºC with constant agitation at 220 rpm. The plasmids were the 
extracted from the E. coli TOP 10 cells using Pure YieldTM  Plasmid Midiprep System 
(Promega) accordingly to manufacturer’s instructions. 
For transfection, 24-well plates were seeded with ~30 000 cells per well and 
allowed to grow till ~80% confluence. The cells were rinsed twice with sterile PBS 
(pH 7.5) and immersed with 500 µl of serum-reduced medium, OptiMEM™ 
(Invitrogen, USA). To prepare the transfection mixture, 1.5 µl of Lipofectamine 
2000™ reagent (Invitrogen, USA) was first  incubated in 23.5 µl of OptiMEM™ at 
room temperature for 5min before being mixed with another 25 µl aliquot of 
OptiMEM™ containing 1-2 µg of the desired plasmid. This mixture was further 
incubated for 10min at room temperature before being added to the HepG2 cells. 
After twelve hours incubation at 37°C with 5% CO2, the transfected cells were 
checked for heterologous expression of GFP and GFP-tagged recombinant  proteins 
using the EVOS fluorescence microscope. Where required, the cells were stained with 
1 µg/ml of Hoechst 33258 (Invitrogen) and 100 mM tetramethylrhodamine, ethyl ester 
(TMRE, Invitrogen) for 30 min at 37°C in the CO2 incubator prior to live imaging 
using the EVOS fluorescence microscope.
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3.6 Cloning PvICP for heterologous expression in Escherichia coli
 The genomic DNA of P. vivax Salvador I strain (MR4, ATCC Manassas 
Virginia) was used as a template for polymerase chain reaction (PCR) amplification of 
PvICP. The thermal cycling sequence was set at 95ºC for 2 min followed by 28 cycles 
of 95ºC for 30s, 55ºC for 1 min and 68ºC for 3 min; and finally 68ºC for 10 min. The 
primers used for cloning are listed in Tables 3.1. The PCR product was purified and 
visualized in an ethidium bromide-stained agarose gel under ultraviolet  (UV) light 
illumination. The band that corresponded to the size of PvICP was excised for 
extraction using the MinElute Gel Purification kit (Qiagen). The purified PvICP was 
ligated into the pCR-Blunt II-TOPO vector using the cloning kit according to 
manufacturer’s instructions (Invitrogen). The incubated reaction mix was added to 
chemically  competent E. coli TOP10 cells (Invitrogen) and left on ice for 1 minute 
before transformation via the heat-shock protocol. After heat-shock, the cells were 
returned on ice for one minute before the addition of S.O.C broth and recovery at 
37ºC for 1h in a rotatory shaker, set at 300 rpm. Following the recovery, the cells were 
plated on Luria-Bertani (LB) agar plate supplemented with kanamycin (50 µg/ml) to 
select for cells harboring the recombinant vector. Single isolated colonies were 
subsequently  picked for culture in the LB broth supplemented with kanamycin (50 µg/
ml). After overnight incubation, the cells were harvested and the plasmids were 
extracted using the Wizard Plus SV Minipreps DNA Purification kits (Promega). To 
verify  the insertion of PvICP, DNA sequencing was performed twice using vector 
specific primers (Table 3.2). 
 The verified pCR-Blunt II-TOPO/PvICP template was subsequently used for 
cloning PvICPc, and the cloning procedures were similarly carried out as described 
above with some changes. Briefly, for bacterial expression, PvICPc was cloned using 
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primers harboring the restrictions sites EcoRI and SalI in the forward and reverse 
primers (Table 3.1), respectively. The amplicon was purified and digested with EcoRI 
and SalI restriction enzymes (NEB) overnight at 37ºC. The destination vector, pMAL-
cx2/His6 was linearized under the same conditions. Following this, DNA products 
corresponding to the sizes of PvICPc and linearized destination vector were purified 
and ligated using T4 DNA ligase (Invitrogen) overnight at 18ºC. E. coli BL21 (DE3) 
cells (Invitrogen) were transformed with the ligated products via electroporation and 
were allowed to recover at 37ºC for 1 h in a rotatory shaker, set at 300 rpm, in LB 
broth. Thereafter, the cells were plated on LB agar plate supplemented with ampicillin 
(100 µg/ml) to select for cells harboring the recombinant vector. Screening and 
verification were similarly  performed as described above. For mammalian expression 
of PvICPc, the gene was amplified using the forward and reverse primers harboring 
BamHI and SalI restriction sites, respectively, instead (Table 3.1). The amplicon was 
digested with BamHI and SalI restriction enzymes and ligated with the linearized 
pXJ40 expression vector using T4 DNA ligase after purification. The recombinant 
plasmid was transformed into E. coli TOP10 cells and DNA sequencing was 
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3.7 Constructing plasmids to express Vx4 in Escherichia coli
 The pET24a expression vector was modified to enable the expression of an 
additional MBP tag. Cloning and purification procedures were similarly  carried out as 
described above. Briefly, MBP was cloned from pMAL-c2x plasmid via PCR using 
specific primers listed in Table 3.1. The purified PCR product and pET24a plasmid 
were digested with BamHI and EcoRI restriction enzymes (NEB) overnight at 37ºC. 
Thereafter, DNA products corresponding to the sizes of MBP and linearized pET24a 
were purified and ligated using T4 DNA ligase (Invitrogen) overnight at 16ºC. 
Electro-competent E. coli Top 10 cells (Invitrogen) was transformed with the ligation 
mix and plated on LB agar supplemented with ampicillin. Transformants were 
screened and DNA sequencing was performed to verify the correct insertion of MBP 
into pET24a. The resultant plasmid hereafter referred to as pET24a/MBP.
 To enable the expression of Vx4 using pET24a/MBP, Vx4 was cloned from 
pMAL-c2x/vx4, derived previously  in the lab, via PCR using specific primers (Table 
3.1). The purified amplicon was digested using EcoRI and XhoI restriction enzymes 
before ligating with the linearized pET24a/MBP plasmid. The ligation mix was used 
to transform electro-competent E. coli BL21 (DE3) cells (Novagen) and transformants 
were selected using LB agar supplemented with kanamycin. The resultant 
recombinant plasmid, pET24a/MBP/Vx4 was sequenced to verify the in-frame 
insertion of Vx4.
 The pET24a/MBP/Vx4 recombinant plasmid was subsequently  used to clone 
Vx4-His6 via PCR amplification. The amplified product and pMAL-c2x were digested 
using EcoRI and SalI restriction enzymes prior ligation. Electro-competent E. coli 
BL21 (DE3) cells was transformed with the ligated products and transformants were 
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selected using LB agar plate supplemented with ampicillin. DNA sequencing was 
performed twice to verify the in-frame insertion of Vx4 in pMAL-c2x plasmid. 
3.8 Heterologous expression of plasmodial proteins in Escherichia coli BL21 
(DE3) cells
 E. coli BL21 (DE3) cells expressing pMAL-c2x or pET24a derived plasmodial 
proteins were cultured overnight in 5 ml LB broth supplemented with ampicillin or 
kanamycin, respectively. Following this, 1 ml of the overnight culture was diluted in 
100 ml of sterile LB medium supplemented with the appropriate antibiotics. The 
cultures were allowed to grow until they reached the mid-log phase (OD600 = 0.6 - 0.8) 
where heterologous expression of the plasmodial proteins was then induced using 1 
mM of isoproply-beta-D-thiogalactopyranoside (IPTG). The induced cultures were 
incubated overnight at 18°C with constant agitation at 220 rpm. Thereafter, the IPTG-
induced cultures were pelleted by centrifugation at 3000 rpm for 5 min at 4°C. The 
resultant supernatant was discarded and the cell pellet was resuspended in ice cold 
PBS (pH 7.5). This washing step was repeated twice before finally  resuspending in 
1.5ml PBS (pH 7.5). The cell suspension was subsequently  transferred into a Bijou 
bottle and subjected to sonication on ice with a 1/8” probe (Sanyo MSE Soniprep) to 
induce cell lysis. Sonication was performed as a nine cycle procedure consisting of 8 s 
pulse and 12 s rest at 10 µm intensity. Thereafter, the cell lysate was subjected to 
centrifugation at 12 000 rpm for 20 min at 4°C to pellet  the cell debris. The resultant 
supernatant was transferred into a fresh microfuge tube, and hereafter referred to as 
the soluble fraction. 
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3.9 Affinity purification and quantification of recombinant plasmodial proteins
 The plasmodial proteins were purified from the soluble fractions via affinity 
chromatography  using the amylose resins (NEB) and nickel-nitrilotriacetic acid (Ni-
NTA) beads (Qiagen). The soluble fraction was first incubated with the amylose resins 
that has been pre-washed twice with PBS (pH 7.5) at  4°C for 30 min in a microfuge 
tube with constant mixing. Thereafter, the resins were pelleted via centrifugation at 
300 rpm for 1 minute. The supernatant was removed and the resins were resuspended 
in ice cold PBS (pH 7.5). This washing step  was repeated thrice and elution was 
performed only for recombinant PvICPc. 
 To elute recombinant PvICPc, PBS (pH 7.5) containing 10 mM  maltose was 
added and incubated for 15 min at 4°C with constant mixing. Thereafter, the amylose 
resin was pelleted by  centrifugation and the purified recombinant PvICPc was 
collected as the supernatant. In procedures that  required cleavage of the MBP fusion 
tag, purified MBP-PvICPc-His6 were incubated overnight at room temperature with 
the factor Xa protease following the manufacturer’s protocol (NEB). 
 In the case of recombinant Vx4 purification, the purified protein was left  
bound to the amylose resin and incubated overnight in PBS (pH 7.5) at 4°C to 
facilitate autocleavage processing of the plasmodial protease. Following this, the 
processed recombinant Vx4 was collected as the supernatant after centrifugation at 
300 rpm for 1 minute. 
 To purify the recombinant proteins from cleaved MBP tag, protein purification 
was repeated using the Ni-NTA beads (Qiagen). Following which, the bound proteins 
were eluted from the beads using PBS (pH 7.5) containing with 250 mM imidazole. 
The concentrations of purified recombinant proteins obtained were quantified using 
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the Bio-Rad protein assay reagent in the Bradford assays performed according to the 
manufacturer’s instructions. 
3.10 SDS-PAGE and Western blot analysis
To analyse the protein sample using SDS-PAGE, the protein samples were first 
mixed with 1X SDS-PAGE gel loading buffer and denatured at 99ºC for 5 min. The 
processed samples were subsequently resolved via the Bio-Rad Mini-Protean system 
using either 8% or 15% polyacrylamide gels. A pre-stained protein standard (Bio-Rad) 
was used in each gel to serve as the molecular weight markers. Electrophoresis was 
performed at 200 V in Tris-glycine electrophoresis buffer and stopped when the 
bromophenol blue dye front reached the bottom of the resolving gel. Thereafter, the 
gels were stained and de-stained by soaking in Coomassie Blue and de-staining 
solution, respectively, to visualize the protein bands. The Bio-Rad Gel-Doc™ system 
equipped with the Quantity One® software Images were used to visualize and 
photograph the gels.
For Western blot analysis, protein samples resolved in SDS-PAGE were left 
unstained after electrophoresis. The resolved samples were transferred to 
polyvinylidene fluoride (PVDF) membranes (Millipore) overnight at 4ºC using the 
Mini-Trans Blot cell (Bio-Rad). The blots were subsequently blocked with 10% (w/v) 
non-fat milk (Bio-Rad) in TBS for 1 h at  room temperature. Thereafter, the 
membranes were probed with mouse anti-His6 (1:1500 dilution, Sigma) primary 
antibodies for 1 h at room temperature with constant mixing. The antibodies used here 
were diluted in 1X TBS containing 1% BSA (w/v) and 0.2% (v/v) Tween-20 (BSA/
TBST). Prior treatment with the peroxidase-conjugated anti-mouse secondary 
antibody (1:3500, Thermo Scientific), the blots were washed five times with TBST 
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buffer. After incubating for 1 h at room temperature with constant mixing, the blots 
were washed with TBST before being developed with the ECL Plus Western Blotting 
Substrate (Thermo Scientific). Thereafter, CL-XPosure films (Thermo Scientific) was 
exposed to the processed blots and the film was processed with SRX-101A film 
developer (Minolta). Duplicate SDS-PAGE gels were ran and stained with Coomassie 
Blue to serve as controls for protein loading.
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3.11 In vitro protease activity assays
 The proteolytic activity of recombinant Vx4-His6 (1.5 µg), papain (400 pM; 
Sigma), cathepsin B (8 nM; BioVision), cathepsin L (8 nM; BioVision), cathepsin S (8 
nM, Calbiochem), human caspases 1 - 10, (0.5 units, Biovision) were assessed in the 
presence and absence of MBP-PvICPc-His6 or PvICPc-His6 using the fluorogenic 
substrate assays as previously  described (Goh et al. 2003). MBP-PvICPc-His6 or 
PvICPc-His6 was incubated with the prepared proteases for 10 min at room 
temperature prior to the addition of respective fluorogenic substrates. Assay buffers 
for cysteine proteases were 10 mM 1,4-dithiothreitol (DTT) in 100 mM sodium 
acetate (pH 5.5) for papain and Vx4; 400 mM  sodium chloride, 10% glycerol, 100 
mM sodium acetate and 10 mM DTT (pH 5.5) for cathepsin L and cathepsin B; 100 
mM KPO4, 5 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM DTT (pH 6.5) 
for cathepsin S; and 10 mM  DTT in 100 mM Tris-HCl (pH 7.5) for Vx4; and 50 mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 50 mM NaCl, 0.1% 
Chaps, 10 mM EDTA, 5% glycerol, and 10 mM DTT (pH 7.2) at 37ºC for caspases. 
Substrates for papain, cathepsin L and Vx4 at pH 5.5 was Z-L-phenyl-L-arginine 4-
methyl-coumaryl-7-amide (Z-Phe-Arg-AMC; Peptide International); cathepsin B at 
pH 5.5 and Vx4 at pH 7.5 was Z-L-arginyl-L-arginine 4-methyl-coumaryl-7-amide 
(Z-Arg-Arg-AMC; Peptide International). Substrates (Biovision) for caspases were 
YVAD-pNA for caspase 1, VDVAD-pNA for caspase 2, DEVD-pNA for caspase 3 
and 7, WEHD-pNA for caspase-4 and –5, VEID-pNA for caspase 6, IETD-pNA for 
caspase 8 and 10 and LEHD-pNA for caspase 9. 
 The autocleavage assays were performed in the presence and absence of 10 µg 
recombinant PvICPc or 30 µM  L-trans-Epoxysuccinyl-leucylamido(4-
guanidino)butane (E-64), a specific cysteine protease inhibitor. 5 µg recombinant 
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MBP-Vx4-His6 was incubated overnight in PBS buffer (pH 7.5) at 4ºC after which, 
the reaction products were analyzed by 12% SDS-PAGE. For the haemoglobinase 
assays, 1.5 µg recombinant  Vx4-His6 was incubated with 3 µg reconstituted human 
haemoglobin (Sigma Aldrich) in the presence and absence of 3 µg PvICPc or 30 µM 
E-64 at  37ºC overnight. Assay buffer used was 100 mM  sodium acetate (pH 4.5, 5.0 
or 5.5) and 10 mM DTT. The reaction products were analyzed by 15% SDS-PAGE.
3.12 HepG2 cell death assay
HepG2 cells transfected with either pXJ40/PvICPc or pXJ40 plasmids were 
visualized under the fluorescent microscopy  to ensure equal transfection efficiencies. 
Different concentrations of tert-butyl hydroperoxide (tBHP, Sigma) were diluted with 
the DMEM medium supplemented with 10% FCS before adding to the transfected 
cells to induce apoptosis. Following which, the treated cells were incubated for 4h at 
37°C in the CO2 incubator. After incubation, the medium was removed and the cells 
were washed twice with PBS (pH7.5) before staining with TMRE and Hoechst 33258 
as described above. Live imaging was performed using the EVOS fluorescence 




 In silico analysis performed in this study was facilitated by programs and 
databases listed in Table 3.2. Details of their applications were discussed in the 
Results and Discussion section.
Analysis Programs / Databases Source
Identification of putative PvICP PlasmoDB.org (Aurrecoechea et al., 2009)
Primary sequence alignment ClustalW (Larkin et al., 2007)
Tertiary structure prediction Swiss Model (Arnold et al., 2006)
3D protein modeling Swiss PDB Viewer (Kaplan and Littlejohn, 2001)
Protein intramolecular interactions 
prediction Protein Interaction Calculator (Tina et al., 2007)
Protein domain prediction Pfam 27.0 (Punta et al., 2012)
Signal peptide prediction SignalP 4.1 Server (Petersen et al., 2011)
Peptidase and inhibitor classification MEROPS (Rawlings et al., 2012)
Table 3.2. Programs and databases used for biocomputational analyses
3.10 Reproducibility of results
 All experiments conducted in this study were performed in duplicates and at 





4.1 Identification and expression of Plasmodium vivax inhibitor of cysteine 
proteases
 Cysteine proteases from both Plasmodium parasite and human host mediate 
biological processes that when left unregulated, can hinder the growth and survival of 
the parasite. Current evidence suggests that the Plasmodium parasite can regulate the 
activities of these enzymes to its advantage via the protein inhibitor, ICP (Pandey  et 
al., 2006; Pei et al., 2013; Rennenberg et al., 2010). Presence of this corresponding 
homologue in P. vivax remains enigmatic. Hence, in order to shed light on this elusive 
area of P. vivax biology, this project began with the investigation of the presence of a 
P. vivax cysteine protease inhibitor via an in silico approach. 
4.1.1 In silico analysis predicted a C-terminal cysteine proteases inhibitor domain
Genome analysis of P. vivax was performed to identify  putative open reading 
frames (ORFs) that may encode for ICPs in the parasite. An ORF (PlasmoDB 
accession identifier PVX_099035) consisting of two exons (exon 1: 67 bp and exon 2: 
1025 bp) and an intron (645 bp) was found to encode a putative PvICP. The protein 
sequence derived from the two exons was predicted to harbor an N-terminal signal 
peptide and a C-terminal cysteine protease inhibitor domain, PvICPc, belonging to the 
I71 family (MEROPS classification) using SignalP and Pfam software (Figure 4.1). 
Separating the signal peptide and PvICPc is a 191 amino acid long peptide sequence 
(PvICPn) of unknown function.
 The putative PvICP shares amino acid similarity of ~30% to that of PbICP, 
PfICP, PcICP and PyICP, and ~49.9% amino acid similarity to that of PkICP (Table 
4.1). However, when the comparison was restricted to the putative cysteine protease 
inhibitor domains, significantly higher similarity of ~60% and ~92% was observed, 
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respectively (Table 4.1). This indicates that the cysteine protease inhibitor domain is 
more conserved amongst the Plasmodium parasites.
Figure 4.1 Illustration of PvICP exons, protein motif and domains
Exon 1 (black) of PvICP was predicted to encode for a signal peptide (red, denoted as 
SP) and exon 2, two putative protein domains, PvICPn (grey) and PvICPc (blue).  
PvICP PbICP PfICP PkICP PcICP PyICP
PvICP 23.2 19.1 42.0 23.9 20.4
PbICP 36.4 34.5 37.9 72.0 79.6
PfICP 31.0 52.8 35.1 33.7 32.3
PkICP 49.9 60.2 55.4 37.7 37.2
PcICP 36.7 84.2 52.8 62.7 67.9
PyICP 33.8 88.7 53.3 56.8 81.1
PvICPc PbICPc PfICPc PkICPc PcICPc PyICPc
PvICPc 47.8 46.9 82.2 48.7 44.9
PbICPc 64.7 43.3 44.9 75.2 85.9
PfICPc 66.9 64.3 45.9 43.7 43.8
PkICPc 92.1 64.7 65.0 46.3 46.5
PcICPc 65.0 86.6 63.7 65.6 74.5
PyICPc 63.5 94.2 66.2 64.7 87.3
Table 4.1 Primary sequence similarity and identity matrix of plasmodial ICPs
The percentage of primary sequence similarity (shaded in grey) and percentage of 
primary sequence identity  (white) of (A) full-length plasmodial ICPs and (B) putative 




4.1.2 3D homology modeling of plasmodial ICP revealed conserved structural 
features
 Crystallographic study of PbICPc has previously revealed a immunoglobulin-
like tertiary structure and identified four motifs (L0, L2, L4 and L6) responsible for 
interacting with FP2 (Figure 2.7) (Hansen et al., 2011). Multiple sequence alignment 
of the putative cysteine protease inhibitor domains revealed that the amino acids 
responsible for interaction with FP2 were highly  conserved except N214, L309 and 
L310 (PbICPc numbering) (Figure 4.2). Of interest in this study are L309 and L310 
where, in PvICPc, they were found to be substituted by phenylalanine (F319) and 
valine (V320), respectively. To investigate if the substitutions may  influence the 
interaction between PvICPc and FP2, 3D homology modeling was performed. 
 The 3D models of PvICPc and other plasmodial ICPs were generated using the 
Swiss Model software to allow 3D structural analysis. The modeling was performed in 
automated mode where the PbICPc:FP2 complex (PDB ID: 3PNR; Hansen et al., 
2011) was selected as the template for modeling. Similar to PbICPc, the resultant 3D 
models of the plasmodial ICPs assume a conserved immunoglobulin-like structure 
(Figure 4.3). However, the loop 3 (L3) regions of the plasmodial ICPs were all found 
to exhibit some structural differences. L3 in PbICPc was found to be a flexible region 
and could not be resolved using X-ray crystallography, plausibly  accounting for the 
differences observed here (Hansen et al., 2011). Considering that L3 is a dynamic 
structure that may not be accurately predicted by 3D homology  modeling, it was thus 
omitted for subsequent in silico protein-protein interaction analysis of PvICPc. 
 To investigate if substitutions in PvICPc may influence its interaction with 
FP2, the 3D model of PvICPc was superimposed onto PbICPc:FP2 complex (PDB ID: 
3PNR; Hansen et al., 2011) for in silico analysis. Despite the change of amino acid 
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residues, no significant steric clashes between PvICPc and FP2 were observed (Figure 
4.4). This suggested that F319 and V320 in PvICP were unlikely to influence the 
functionality of PvICPc against the plasmodial cysteine protease. 
Immunoglobulin-like proteins are commonly  known to possess disulphide 
bonds and hydrophobic clusters to help maintain structural stability (Salmon et  al., 
2006). Protein sequence analysis of the PvICPc showed that it lacks the two cysteine 
residues required for the disulphide bond formation. However, hydrophobic amino 
acid residues on the putative β-strands were found to be organized in an alternating 
fashion and were predicted to form inter-hydrophobic interactions at the protein core 
of PvICPc using Swiss PdbViewer and Protein Interaction Calculator software (Figure 
4.5). When the analysis was extended to the other plasmodial cysteine protease 
inhibitor domains, similar findings were observed (Figure 4.5). Hence, it was 
postulated that plasmodial ICPs rely mainly  on these hydrophobic interactions to 
maintain their structural stability.
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Figure 4.2 Multiple sequence alignment of the C-terminal domains of putative 
plasmodial ICPs 
Organization of secondary  structure elements in PbICPc is presented above the 
sequence alignment and the flexible region unresolved in previous study  is 
represented by a dotted line. Loop  regions and amino acid residues responsible for 
interaction are boxed and indicated with an asterisk, respectively. Amino acid residues 
in putative secondary structures are coloured red (α-helices) and grey (β-strands). 
Hydrophobic amino acid residues in putative β-strands predicted to form hydrophobic 
interactions in the protein core are highlighted in yellow and aromatic amino acid 
residues predicted to form aromatic interaction are underlined.
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Figure 4.3 The C-terminal domains of plasmodial ICPs were predicted to possess 
an immunoglobulin-like structure
Protein sequences of plasmodial ICPc were submitted to Swiss-Model and their 3D 
models were generated using a solved protein structure (PDB id: 3pnr). Their 
computed TM-alignment scores without loop 3 were 0.95963 for PvICPc; 0.96759 for 
PfICPc; 0.96574 for PcICPc; 0.96093 for PkICPc and 0.96617 for PyICPc. The 3D 
models are coloured in succession of their secondary structures and loop 3 of each 
model was coloured pink. 
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Figure 4.4 3D Modeling of interaction between FP2 and PvICPc
The modeled PvICPc was superimposed onto the PbICPc:FP2 protein complex 
template (PDB ID: 3pnr). Details of interactions between PvICPc (blue) and FP2 (red) 
are shown in the insets. The appended “b” and “v” indicate amino acid residues 
responsible for interaction with PbICPc and PvICPc respectively.
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Figure 4.5 Hydrophobic residues found on the beta strands of plasmodial ICPc 
were predicted to form a hydrophobic core
The Protein Interaction Calculator was used to identify amino acid residues that may 
form intra-molecular hydrophobic and aromatic interactions in the cysteine protease 
domain of plasmodial ICPs. These amino acid residues were coloured orange and 
presented as ball and stick structures in the 3D models.
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4.1.3 PvICPc was solubly expressed as a functional recombinant protein
Findings from the biocomputational analysis indicate that the PvICP is 
encoded by  the ORF PVX_099035. To evaluate functionality  of this putative protein, 
this study next attempted to obtain sufficient amounts of recombinant PvICPc for 
subsequent in vitro biochemical characterization assays. DNA sequence encoding the 
PvICP was first amplified from the genomic DNA of P. vivax Salvador I strain, and 
cloned into the pCR-BluntII-TOPO cloning vector (Figure 4.6A). The resultant pCR-
Blunt-II-TOPO/PvICP served as a template for the subsequent cloning of DNA 
sequence encoding the putative PvICPc of amino acid position 213 – 364 (Figure 
4.6B). The amplicon was cloned into the pMAL-c2x/His6 expression vector and 
PvICPc was expressed as a fusion protein with N-terminal MBP and C-terminal His6 
tags (Figures 4.7C). DNA sequencing was performed twice to verify  the in-frame 
insertion of the gene sequence. The resultant recombinant MBP-PvICPc-His6 was 
found to be solubly expressed and the recombinant protein was purified by  affinity 
chromatography  using amylose resin. As shown in the SDS-PAGE analysis (Figure 
4.7), a prominent protein band of ~67 kDa that corresponded to the predicted size of 
MBP-PvICPc-His6 was observed. The purified recombinant MBP-PvICPc-His6 was 
incubated with factor Xa overnight at room temperature to cleave the MBP tag. The 
resultant PvICPc-His6 was purified using Ni2+ affinity  chromatography and SDS-
PAGE analysis revealed a prominent protein band of ~20 kDa that corresponded to the 
predicted size of PvICPc-His6 (Figure 4.7).
 To evaluate the functionality  of the recombinant PvICPc, its inhibitory activity 
against the papain protease was tested using fluorometric assays. The proteolytic 
activity of papain against the Z-Phe-Arg-AMC substrate was measured in increasing 
concentrations of MBP-PvICPc-His6 or PvICPc-His6. As illustrated in Figure 4.8, the 
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proteolytic activity of papain was progressively inhibited with increasing 
concentrations of PvICPc, suggesting that PvICPc is a functional inhibitor of papain. 
MBP-PvICPc-His6 and PvICPc-His6 exhibited similar inhibitory activities against 
papain indicating that the MBP tag does not interfere with the inhibitory  activity of 
recombinant PvICPc (Figure 4.8). Hence, MBP-PvICPc-His6 was used for subsequent 
assays.
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 (A)         (B)
 (C)               (D)
Figure 4.6 DNA sequences encoding PvICPc were amplified using PCR
Gel visualization was performed to evaluate (A) the PCR amplification of PvICP from 
the genomic DNA of P. vivax, (B) the restriction digestion of pCR-Blunt II-TOPO/
PvICP recombinant vector using EcoRI restriction enzyme (C) the PCR amplification 
of PvICPc from pCR-Blunt II-TOPO/PvICP for insertion into pMAL-c2x, (D) the 
restriction digestion of pmal-c2x/PvICPc recombinant vector using EcoRI and SalI 
restriction enzymes. The PvICP and PvICPc amplicons were represented by the 
1092bp and 472bp bands, respectively. Legend: M, DNA marker. 
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Figure 4.7 SDS-PAGE analysis of purified PvICPc and Vx4 recombinant proteins
Recombinant PvICPc purified using (1) amylose resin and (2) subsequent purification 
using Ni-NTA resin after incubation with factor Xa.
Figure 4.8 The recombinant PvICPc is an inhibitor of papain protease
The proteolytic activity  of papain was evaluated in the presence or absence of either 
MBP-PvICPc-His6 or PvICPc-His6 using fluorometric assays. The protease activity in 
the absence of the recombinant PvICPc was considered as 100% and the percentage of 
residual activity in the presence of increasing concentrations of either MBP-PvICPc-
His6 or PvICPc-His6 was calculated. The ± standard deviations are represented by the 
error bars.
73
4.2 Heterologous expression and functional characterization of recombinant Vx4
 Plasmodial ICPs have been reported to interact and inhibit the proteolytic 
activities of endogenous papain-like cysteine proteases (Pandey  et al., 2006; Pei et al., 
2013). Following the identification of a functional ICP in P. vivax, it is the next aim of 
this project was to investigate if this functionality is conserved in PvICP through in 
vitro biochemical assays. Hence, the next part of study entailed the expression and 
purification of an active P. vivax papain-like cysteine protease, vivapain 4. 
  Biochemical characterization of plasmodial cysteine proteases has been 
extensively  reported using bacterial expressed recombinant proteins (Rosenthal, 
2011). In most of these studies, the recombinant proteases were expressed as insoluble 
proteins that formed inclusion bodies in the bacterial expression host. To recover their 
solubility and activity  for subsequent studies, it was necessary to extract  the inclusion 
bodies and denature them before allowing them to refold under optimized refolding 
conditions (Na et al., 2004; Sijwali et al., 2001a; Sijwali et al., 2001b). Not only is this 
process tedious, the refolding process also requires extensive optimization and may 
only offer limited success in obtaining active recombinant plasmodial cysteine 
proteases (Goh et al., 2003). However, expression study performed by Goh et al. 
(2003) reported that the soluble and active expression of recombinant FP2A was 
achievable with the fusion of an N-terminal MBP tag. Using this strategy, Vx4 
previously  cloned in the laboratory was heterologously  expressed in E. coli BL21 
(DE3) cells as a soluble fusion protein. 
 Recombinant Vx4 was expressed as a fusion protein tagged with an N-terminal 
MBP using pMAL-c2x. The purified Vx4 fusion protein exhibited autocleavage 
activity after overnight incubation in PBS, pH 7.5, at 4°C. The autocleavage 
processing of MBP-Vx4 yielded two prominent bands in SDS-PAGE analysis, ~42 
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kDa and ~32 kDa, that corresponded to the predicted size of mature Vx4 and cleaved 
MBP tag, respectively. The intensities of the bands in the SDS-PAGE analysis 
suggested that  the cleaved MBP tag was a major component of the incubated fraction 
after the autocleavage process. Presence of the cleaved MBP tag was found to hinder 
accurate quantification of mature Vx4 and was thought to affect the haemoglobinase 
activity of the mature Vx4. Hence, it was the objective of this study  to isolate the 
mature Vx4 from the cleaved MBP tag for subsequent biochemical characterization 
studies.
4.2.1 Development of an efficient purification strategy for recombinant Vx4 
 Initially, recombinant MBP-Vx4 purified from the cell free lysate was left bound 
on the amylose beads overnight  in PBS, pH7.5 at 4°C for autocleavage processing to 
occur. It was thought that after the autocleavage processing, the mature Vx4 would be 
released as a free protein into the soluble fraction while the cleaved MBP tag remains 
bound to the amylose resin. However, a significant amount of MBP was found to be 
released together with the matured Vx4 into the soluble fraction after the autocleavage 
processing. Hence, it appeared that the extraction of mature Vx4 would require an 
additional purification step  and thus attempts were made to add an additional tag, 
His6, at the C-terminus of Vx4. This two-step purification strategy is summarized in 
Figure 4.9.
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 Figure 4.9 Purification strategy of Recombinant Vx4
(1) The soluble fraction of the cell lysate was incubated with the amylose resin beads 
and (2) washed with PBS, pH 7.5, to remove any unbound proteins. (3) The bound 
MBP-Vx4-His6 fusion protein autocleaved itself and Vx4-His6 was released into the 
soluble fraction along with some cleaved MBP tag. (4) The filtrate was harvested and 
incubated with the Ni-NTA beads which facilitated (5) the removal of any 
contaminating MBP tag after washing with PBS. (6) Elution was performed using 
PBS buffer, pH 7.5, supplemented with 250mM imidazole and (7) the purified Vx4-
His6 was harvested for further processing with the centrifugal device, Amicon, prior to 
biochemical characterization. 
Legend:  , MBP tag; , Vx4; , His6 tag; , Amylose resin; , Ni-NTA 
beads; , contaminating proteins; , auto cleavage; , imidazole.
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4.2.1.1 pET24a was modified to enable the expression of a dual-tagged 
recombinant Vx4
 To facilitate the expression of recombinant Vx4 fused with an N-terminal MBP 
and a C-terminal His6 purification tag, modification of the pET-24a expression vector 
was performed. DNA sequence encoding MBP was cloned from the pMAL-c2x 
expression vector and inserted in between the BamHI and EcoRI restriction sites on 
the multiple cloning sites of pET24a expression vector (Figure 4.10). The resultant 
pET-24a/MBP expression vector was propagated using E. coli TOP10 cells and 
sequenced twice to verify in-frame insertion of MBP.  
 (A)     (B)
Figure 4.10 Sub-cloning MBP into pET-24a expression vector
Gel visualization was performed to evaluate (A) the PCR amplification of MBP from 
pMAL-c2x and (B) the restriction digestion of pET24a/MBP recombinant  vector 
construct using EcoRI and BamHI restriction enzymes. (A) The amplified MBP was 
represented by a prominent band of ~1101bp. (B) The positive construct of pET24a/
MBP recombinant vector was indicated by representative bands of pET24a and MBP. 
M represents the DNA marker.
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4.2.1.2 MBP-Vx4-His6 expressed using pET24a/MBP did not exhibit autocleavage 
activity
 Vx4 was amplified from pMAL-c2x/Vx4 and inserted between the EcoRI and 
XhoI restriction sites of pET-24a/MBP (Figure 4.11). Heterologous expression in E. 
coli BL21 (DE3) cells yielded the soluble fusion protein, MBP-Vx4-His6. SDS-PAGE 
analysis of the fraction purified using amylose resins revealed a prominent protein 
band of ~78 kDa that corresponded to the predicted size of MBP-Vx4-His6 (Figure 
4.12). The purified recombinant protein was subsequently  incubated overnight in PBS 
at 4°C to promote the autocleavage processing of recombinant Vx4. Surprisingly, 
SDS-PAGE analysis of the incubated fraction revealed that the intensity of band 
representing MBP-Vx4-His6 remained unchanged (Figure 4.12). This suggested that 
the recombinant Vx4 exhibited a reduction in autocleavage activity. 
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     (A)              (B)
Figure 4.11 Sub-cloning Vx4 into pET-24a/MBP expression vector
Gel visualization was performed to evaluate (A) the PCR amplification of Vx4 from 
pMAL-c2x/Vx4 and (B) the restriction digestion of pET24a/MBP/Vx4 recombinant 
vector construct using BamHI and XhoI restriction enzymes. (A) The amplified Vx4 
was represented by a prominent band of ~729 bp. (B) The positive construct of 
pET24a/MBP/Vx4 recombinant vector was indicated by representative bands of 
pET24a/MBP and Vx4. Legend: M, DNA marker.
Figure 4.12 SDS-PAGE analysis of purified Vx4 fusion protein
Soluble fraction was (1) purified using amylose resin and (2) incubated overnight in 
PBS, pH 7.5, at 4°C. The incubated soluble fraction was further (3) purified using Ni2+ 
resins. M represents the protein marker.
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4.2.1.3 Recombinant Vx4 exhibited autocleavage activity when expressed with 
pMAL-c2x
 To investigate if the change of expression vector to pET24a affected the 
autocleavage activity of recombinant Vx4, pMAL-c2x was next used to express the 
fusion protein. Vx4-His6 was amplified from pET24a/MBP/Vx4 using PCR and the 
amplicon was digested with EcoRI and SalI restriction enzymes (Figure 4.13A). The 
digested products were inserted into pMAL-c2x vector for heterologous expression in 
E. coli BL21 (DE3) cells (Figure 4.13B). The resultant MBP-Vx4-His6 fusion protein 
was solubly  expressed and SDS-PAGE analysis revealed a prominent  band that 
corresponded to the predicted size of MBP-Vx4-His6, ~78 kDa, (Figure 4.14A). 
Unlike the fusion protein expressed using pET24a/MBP, MBP-Vx4-His6 expressed 
using the pMAL-c2x vector was observed to exhibit autocleavage activity  upon 
overnight incubation in PBS at 4°C. As shown in the SDS-PAGE analysis, the 
intensity of the ~78 kDa band of the incubated protein fraction was significantly 
reduced and two protein bands, ~42 kDa and ~32 kDa, that corresponded to the 
predicted size of MBP and Vx4-His6, respectively, were observed (Figure 4.14A). The 
cleaved Vx4-His6 was further purified using Ni2+ affinity chromatography and SDS-
PAGE analysis of the purified fraction yielded a prominent band of ~32 kDa. 
Consistent with the SDS-PAGE analysis, western blot performed using antibodies 
raised against His6 polypeptide detected bands representing the MBP-Vx4-His6 (~78 
kDa) and Vx4-His6 (~32 kDa) (Figure 4.14B). 
80
    (A)               (B)
Figure 4.13 Sub-cloning Vx4-His6 into pMAL-c2x expression vector
Gel visualization was performed to evaluate (A) the PCR amplification of Vx4-His6 
from pET24a/MBP/Vx4 and (B) the restriction digestion of pMAL-c2x/ Vx4-His6 
recombinant vector construct using restriction enzymes EcoRI and SalI. (A) The 
amplified Vx4-His6 product was represented by a prominent band of ~921 bp. (B) The 
positive construct of pMAL-c2x/Vx4-His6 recombinant vector was indicated by 
representative bands of pMAL-c2x and Vx4-His6. Legend: M, DNA marker.
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           (A)
            (B)
Figure 4.14 (A) SDS-PAGE and (B) Western blot analysis of purified Vx4 fusion 
protein
Soluble fraction was (1) purified using amylose resin and (2) incubated overnight in 
PBS, pH 7.5, at 4°C. The incubated soluble fraction was further (3) purified using Ni2+ 
resins. (4) - (6) correspond to lane (1) – (3), respectively, in western blot analysis. M 
represents the protein marker.
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4.2.1.4 Dual-tagged expression strategy improved purification of recombinant 
Vx4
Results from this expression study demonstrated that the additional C-
terminal His6 tag facilitated the purification of mature Vx4 and did not influence 
the protease’s autocleavage activity. Instead, it appears that the pET24a/MBP 
expression vector was unsuitable for producing active recombinant Vx4. One 
possible factor that may account for this observation was the change in rate of 
recombinant protein expression in the bacterial host  cell when different expression 
vectors were used. The pET24a expression vector harbors a relatively stronger T7 
promoter that can significantly  increase the level of fusion protein produced. The 
higher levels of Vx4 fusion protein produced may have exhausted the protein 
chaperoning capacity of the bacterial host cell and led to improper folding of 
newly synthesized Vx4 (Kyratsous et al., 2009). However, instead of forming 
insoluble aggregates, the highly  soluble MBP fusion partner may have the 
recombinant Vx4 kinetically  trapped in a folding intermediate that is no longer 
susceptible to aggregation (Nallamsetty and Waugh, 2006). Hence, although 
soluble MBP-Vx4-His6 was obtained using pET24a as the expression vector, a 
loss in autocleavage activity  was observed. Nevertheless, soluble and active MBP-
Vx4-His6 was obtained using pMAL-c2x and mature Vx4 was successfully 
purified using the dual-tagged purification strategy. With this optimised protocol, 
purer samples of mature Vx4 can be obtained for subsequent biochemical 
characterization and inhibitor studies.
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4.2.3 Investigating the haemoglobinase activity of Vx4
 One of the main physiological functions of plasmodial papain-like cysteine 
proteases is the degradation of host haemoglobin in the parasite food vacuole 
(Rosenthal, 2011). Interestingly, FP2 was reported to interact with its haemoglobin 
substrate via an unusual 14 amino acid long β-hairpin motif, haemoglobin binding 
motif, that protrudes out of the protein (Pandey et  al., 2005). To investigate if this β-
hairpin motif is conserved in Vx4, 3D homology modeling was performed using the 
3D crystal structure of FP3 as a template (PDB ID:3BPM; Kerr et al. 2009). As shown 
in the 3D model of Vx4, β-hairpin motif protruding out of Vx4 was found at amino 
acid positions V427 to K440 (Figure 4.15). To verify if Vx4 can utilize haemoglobin 
as its substrate, the haemoglobinase assay was performed using the purified Vx4-His6 
fusion protein.
Figure 4.15 3D modeling of Vx4 revealed a haemoglobin binding domain
The 3D structure of Vx4 was modeled using the FP3 template (PDB ID:3bpm, Kerr et 
al. 2009). Analysis revealed that a conserved β-hairpin motif used for interacting with 
the haemoglobin substrate (indicated with a white box) is present in the proteolytic 
domain of Vx4. TM-alignment score computed was 0.999, where values > 0.5 
indicates that the models share the same fold.
84
4.2.3.1 Recombinant Vx4 exhibited haemoglobinase activity
 Previously in the lab, recombinant plasmodial cysteine protease 
haemoglobinases were found to be inactive against reconstituted human haemoglobin 
substrate (personal communications). It was postulated that the MBP fusion tag may 
hinder interaction between the plasmodial proteases and the haemoglobin substrate 
resulting in the false absence of haemoglobinase activity. However, in this study, Vx4-
His6 fusion protein was similarly found to be inactive against its partnering 
haemoglobin substrate initially. This implies that the MBP tag may not be the factor 
responsible for the lack of haemoglobinase activity. Since degradation of haemoglobin 
is known to be a pH specific process, optimization was performed with the aim to 
specifically control the pH conditions of the haemoglobinase assays. To ensure that 
the assays were carried accurately in the stipulated pH conditions stipulated, buffer 
exchange was carried out to calibrate the pH conditions of each Vx4 aliquots prior to 
the assays. The processed Vx4 aliquots were added to specific reaction mixes each 
containing the haemoglobin substrate and a reducing agent, either DTT or glutathione. 
The assays were performed at 37ºC to simulate the temperature in human, and small 
aliquots from each reaction mixes were extracted at different time points for SDS-
PAGE analysis. Interestingly, this solved the problem and recombinant Vx4 was found 
to degrade the haemoglobin substrate in vitro as discussed below. 
 The haemoglobinase activity of recombinant Vx4 was evaluated over a range of 
pH conditions, pH 4.5 to pH 7. Degradation of the haemoglobin substrate is marked 
by the loss of a 17 kDa band in SDS-PAGE analysis that corresponded to the 
molecular weight of the haemoglobin substrate. SDS-PAGE analysis of the 
biochemical reactions indicated that Vx4 exhibited proteolytic activities against 
haemoglobin at pH 4.5, pH 5.0 and pH 5.5 (Figure 4.16A) and complete degradation 
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was observed upon overnight incubation (Figure 4.16B). Similarly, when DTT was 
substituted with glutathione, recombinant Vx4 was similarly  found to degrade the 





Figure 4.16 SDS-PAGE analysis of Vx4 haemoglobinase assay
(A) The 18kDa bands in the SDS-PAGE analysis represented the haemoglobin 
substrate. The degradation of the haemoglobin substrate is indicated by the absence of 
the 18kDa band in each reaction. Legend: M, Protein marker; Lane A, haemoglobin 
substrate only; Lane B, haemoglobin substrate with recombinant Vx4-His6. (B) The 
haemoglobin assay was performed at pH 5.5 and samples were taken at different time 
point for SDS-PAGE analysis. Legend: M, Protein marker; Lane 1, 30 minutes; Lane 
2, 60 minutes; Lane 3, 90 minutes; Lane 4, 120 minutes; Lane 5, 150 minutes; Lane 6, 
180 minutes; Lane 7, overnight; Lane 8, negative control. (C) The haemoglobin assay 
was performed with different concentrations of GSH at pH 5.5 Legend: M, Protein 
marker; ctrl, haemoglobin substrate only; Vx4, haemoglobin substrate with 
recombinant Vx4-His6.
87
4.2.3.2 Putative cellular functions of Vx4 in P. vivax 
 Haemoglobin degradation in Plasmodium parasite occurs in acidified food 
vacuoles in the presence of a reducing agent, glutathione (Abu Bakar et al., 2010; 
Rosenthal, 2011). In this study, recombinant Vx4 was found to exhibit 
haemoglobinase activity against haemoglobin at pH values 4.5, 5.0 and 5.5 in the 
presence of 10 mM DTT. When DTT was substituted with 1 to 3mM of glutathione, 
haemoglobinase activity of Vx4 was similarly observed. These findings suggest that 
Vx4 is a functional haemoglobinase that may play  a role in P. vivax haemoglobin 
metabolism in vivo. Consistent with this postulation, a study subsequently  performed 
by Na et al. (2010) reported the detection of Vx4 in the food vacuole of P. vivax using 
Vx4 specific antibodies. Similarly, when recombinant Vx4 was incubated with the 
haemoglobin, degradation of substrate was observed in pH 4.5, 5.0 and 5.5 in the 
presence of 10 mM DTT. However, the haemoglobinase activity  of Vx4 was not tested 
using glutathione, the native cellular reducing agent. Thus, it was uncertain if Vx4 was 
active against the haemoglobin substrates in the parasite food vacuole. 
Notwithstanding this, Vx4 was shown here to maintain its haemoglobinase activity  in 
the presence of glutathione. Collectively, these findings were indicative of Vx4’s 
physiological role in the haemoglobin degradation process.  
 Interestingly, Vx4 was also detected in the cytoplasm of P. vivax, suggestive of 
its functional roles beyond that of haemoglobin degradation. Biochemical 
characterization of recombinant Vx4 revealed that the plasmodial protease has 
proteolytic activity  against fluorometric substrates and cytoskeletal proteins at neutral 
pH. This suggested that Vx4 is likely to retain its proteolytic activity in the parasite 
cytoplasm, and may play a role in mediating the remodeling of cytoskeletal structures 
and transport of haemoglobin (Na et al., 2010). Considering that cysteine proteases 
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possess relatively unspecific activities (Storer and Menard, 1994), unregulated 
proteolytic activity of Vx4 in the cytoplasm can potentially be perilous to the P. vivax 
parasite. Thus, this led to the question on how P. vivax may  regulate the activity of 
Vx4 outside the confines of the parasite food vacuole.
89
4.3 Evaluation of PvICPc inhibitory activity against recombinant Vx4
 Studies have demonstrated that plasmodial ICP can inhibit the proteolytic 
activities of endogenous cysteine proteases in vitro (Pandey  et al., 2006; Rennenberg 
et al., 2010). In addition, interaction studies have identified plasmodial cysteine 
proteases haemoglobinases, (hereafter referred to falcipains and its corresponding 
homologues in other Plasmodium parasites) as principal targets of plasmodial ICPs 
(Pandey et al., 2006; Pei et al., 2013). These observations raise the possibility  that 
Vx4 may be a potential target protease of PvICPc. To evaluate this postulation, the 
next objective of this study was to investigate the inhibitory profile of PvICPc against 
Vx4 in vitro. 
4.3.1 PvICPc exhibited potent inhibitory activity against Vx4 in fluorometric 
assays 
 The substrate specificity of recombinant Vx4 was reported to change under 
different pH conditions where Vx4 preferentially  cleaves the Z-Phe-Arg-AMC 
substrate at pH 5.5 and the Z-Arg-Arg-AMC substrate at pH 7.5 (Na et al., 2010). This 
pH-dependent substrate specificity  was found to be mediated by a glutamine residue 
(Glu180) that delineates the S2 subsite of Vx4 substrate binding pocket. Changes in 
pH conditions were proposed to cause variations in the Glu180 side chain position 
hence, altering its interaction with the substrate (Na et al., 2010). 
 In this study, 3D structural analysis of the modeled PvICPc and Vx4 
superimposed on the PbICPc:FP2 protein complex template (PDB ID: 3pnr; Hansen et 
al. 2011) revealed potential interaction between the S2 subsite of Vx4 and L4 loop of 
PvICPc (Figure 4.17). This thus raises the question whether pH-induced changes in 
the S2 subsite of Vx4 would influence the interaction between Vx4 and PvICPc. 
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Figure 4.17 3D Modeling of interaction between Vx4 and PvICPc
The modeled PvICPc and Vx4 were superimposed onto the PbICPc:FP2 protein 
complex template (PDB ID: 3pnr). Details of interactions between PvICPc (blue) and 
Vx4 (orange) are shown in the insets. The appended “b” and “v” indicates amino acid 
residues responsible for interaction from PbICPc and PvICPc respectively.
91
 To gather a better understanding, the inhibitory activity of recombinant 
PvICPc against Vx4 was evaluated at both pH 5.5 and pH 7.5 using the fluorometric 
assays. Vx4 was incubated with Z-Phe-Arg-AMC and the Z-Arg-Arg-AMC substrates 
at pH 5.5 and pH 7.5, respectively, in different concentrations of recombinant PvICPc. 
The proteolytic activity of Vx4 was found to decrease with increasing concentrations 
of MBP-PvICPc-His6 and complete inhibition was observed in the presence of 1 nM 
MBP-PvICPc-His6 under both pH conditions (Figure 4.18). Since a similar inhibition 
pattern was observed under both pH conditions, it  suggested that  variations at the S2 
subsite of Vx4 does not influence the interaction between the protease and PvICPc.
Figure 4.18 PvICPc fusion protein inhibited the activity of recombinant Vx4
The proteolytic activity of Vx4-His6 was evaluated with or without of MBP-PvICPc-
His6 under two pH conditions, pH 5.5 and pH 7.5, using fluorometric assays. The 
protease activity in the absence of MBP-PvICPc-His6 protein was considered as 100% 
and the percentage of residual activity in the presence of different  concentrations of 
MBP-PvICPc-His6 was calculated. The ± standard deviations are represented by the 
error bars.
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4.3.2 Autocleavage and haemoglobinase activities of Vx4 were suppressed by 
PvICPc in vitro
 To further investigate the potential relevance of Vx4 inhibition by recombinant 
PvICPc, the autocleavage and haemoglobinase activities of recombinant Vx4 were 
evaluated in the presence and absence of MBP-PvICPc-His6. For the autocleavage 
assay, MBP-Vx4-His6 was incubated overnight in PBS, pH 7.5, at 4ºC in the presence 
or absence of MBP-PvICPc-His6. The reaction mix was subsequently analyzed using 
SDS-PAGE to evaluate the autocleavage activity  of recombinant Vx4. In the absence 
of the PvICPc, SDS-PAGE analysis revealed two protein bands ~32 kDa, and ~42 kDa 
that corresponded to the recombinant Vx4-His6 and MBP tag (Figure 4.19). However, 
when MBP-PvICPc-His6 is present, a single band of ~78 kDa that corresponded to the 
unprocessed MBP-PvICPc-His6 was observed in the SDS-PAGE analysis. 
 For the haemoglobinase assay, recombinant Vx4 was incubated with the 
haemoglobin substrates at  pH 4.5, 5.0 and 5.5 in the presence or absence of MBP-
PvICPc-His6. Following overnight incubation at 37ºC with 10 mM  DTT, the reaction 
mixes were analyzed using SDS-PAGE to evaluate the degradation statues of 
haemoglobin. In the absence of MBP-PvICPc-His6, protein bands that corresponded to 
the molecular weight of the haemoglobin, 17 kDa, were absent in the SDS-PAGE 
analysis. This suggests that the haemoglobin substrate has been hydrolysed by 
recombinant Vx4 (Figure 4.20). However, in reactions containing MBP-PvICPc-His6, 
the 17 kDa protein bands were present in the SDS-PAGE analysis, indicating that 
recombinant Vx4 was unable to degrade the haemoglobin substrate (Figure 4.20). 
Collectively, these findings demonstrated that PvICPc can inhibit the autocleavage 
and haemoglobinase activities of Vx4 in vitro. 
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Figure 4.19 PvICPc fusion protein inhibited the autocleavage activities of 
recombinant Vx4
MBP-Vx4-His6 (5µg) was incubated in PBS, pH 7.5, in the presence or absence of a 
cysteine protease inhibitor, either MBP-PvICPc-His6 (10 µg) or E-64 (30 µM), at 4ºC 
overnight. The assays were analyzed using 12% SDS-PAGE. 
Figure 4.20 PvICPc fusion protein inhibited the haemoglobinase activities of 
recombinant Vx4
MBP-Vx4-His6 (1.5 µg) was incubated with reconstituted human haemoglobin (3 µg) 
under different pH conditions supplemented with 10mM DTT, in the presence or 
absence of a cysteine protease inhibitor, either MBP-PvICPc-His6 (10 µg) or E-64 (30 
µM), at 37ºC overnight. Degradation of haemoglobin is indicated by the absence of a 
prominent protein band in the 15% SDS-PAGE analysis. Results presented here were 
representative of three independent assays.
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4.3.3 PvICPc is a potential endogenous regulator of Vx4 in Plasmodium vivax
 In P. vivax, Vx4 has been detected within the parasite food vacuole and 
cytoplasm (Na et al., 2010). Further characterization of Vx4 suggested that it is 
proteolytically active in both compartments where haemoglobin and cytoskeletal 
proteins may be targeted for degradation, respectively. In this study, PvICPc was 
shown to inhibit the proteolytic activity of recombinant Vx4 in vitro in pH conditions 
simulating the food vacuole and cytoplasm of the parasite. In addition, recombinant 
PvICPc was demonstrated to inhibit the native process, i.e. haemoglobin degradation 
and autocleavage activation, performed by  Vx4 in vitro. The inhibition of 
haemoglobinase activity by PvICPc could potentially be important in the event that 
the membrane integrity  of food vacuole is compromised. PvICPc can interact with 
Vx4 to halt the generation of toxic haeme byproducts and prevent  its leakage into the 
parasite cytoplasm. Furthermore, PvICPc may also serve to protect the parasite 
cytosolic proteins from undesired proteolytic damage by Vx4 localized in parasite 
cytoplasm, and possible leakage of other vivapains from the parasite food vacuole. 
Indeed, the presence of cysteine protease inhibitors in many  organisms was thought to 
primarily  protect the cytosolic proteins against active cysteine proteases during 
accidental release (Klotz et al., 2011; Rzychon et al., 2003; Saric et al., 2011). 
 In addition to their potential protective roles, cysteine protease inhibitors have 
also been proposed to regulate protease zymogen activation in protozoan parasites. In 
Trypanosoma parasites, manipulation of chagasin expression had unveiled the inverse 
relationship  of intracellular chagasin levels and the overall intracellular content of 
active endogenous cysteine proteases (Santos et  al. 2007; Santos et al. 2005; Santos et 
al. 2006). Since the active form of cysteine proteases was thought to result from the 
autocleavage of zymogens, chagasin was proposed to influence the autocleavage 
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process and in turn, the availability of active cysteine proteases (Santos et al. 2007; 
Santos et al. 2005; Santos et al. 2006). The presence of such regulatory  mechanism in 
P. vivax would allow the parasite to have additional control on the activation of Vx4 in 
a spatial temporal specific manner after their expression.
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4.4 Investigation on the potential functionalities of PvICPc in the human host cell
 Hepatocytes infected with P. berghei parasites were found to be protected from 
chemically  induced apoptosis in vitro and in the rodent malaria model (van de Sand et 
al., 2005). Disruption of hepatocyte apoptosis was proposed to promote the survival of 
P. berghei parasites during the liver stage development (van de Sand et al., 2005). 
Current evidence suggests that the presence of PbICPc may block the host apoptotic 
mechanism through the inhibition of pro-apoptotic cysteine proteases, i.e. cathepsins 
and caspases (Pandey et al., 2006; Rennenberg et al., 2010). Although human caspase 
3 and caspase 8 had been proposed to be potential protease targets of PbICPc during 
the suppression of HepG2 apoptosis, contrary results had been reported (Hansen et al., 
2011). Both recombinant PfICP and PbICP were later shown to be inactive against 
human caspases 3 and 8, leading to the hypothesis that the suppression of hepatocyte 
apoptosis may occur via a caspase-independent pathway. However, caspase 8 is one of 
the four initiator caspases found in the human cells, and it responds primarily  to 
external stimuli, such as TNF, to activate cellular apoptosis. Thus, the lack of caspase 
8 inhibition by  either PbICP or PfICP was not sufficient to prove that caspase 
inhibition was absent during the suppression of hepatocyte apoptosis. In addition, it is 
not known if plasmodial ICP could exert its inhibitory activity against other important 
executioner caspases, i.e. caspases 6 and 7. Hence, to gather a better understanding, an 
in vitro cell death assay  was performed to evaluate PvICPc functionality against 
chemically  induced apoptosis in HepG2 cells. In addition, inhibitory activities of 
PvICPc against human caspases 1 to 10 were investigated to obtain more clues on 
how plasmodial ICPs may disrupt host cell apoptosis. 
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4.4.1 PvICPc localized in the cytoplasm of transfected HepG2 cells
 To investigate whether PvICPc may similarly possess anti-apoptotic function 
similar to PbICPc in human hepatocytes, PvICPc was heterologous expressed in the 
cytoplasm of HepG2 cells. DNA sequence encoding PvICPc was first sub-cloned from 
pCR-Blunt-II-TOPO/PvICPc into the pXJ40 mammalian expression vector (Figure 
4.21). The resultant pXJ40/PvICPc vector encoded an N-terminally GFP-tagged 
PvICPc fusion protein. HepG2 cells were grown to approximately 90% confluency  in 
24-well plates before being transfected with the recombinant vector. Heterologous 
expression of GFP-PvICPc in HepG2 cells was visualized under fluorescence 
microscopy 16 hours after transfection. As shown in the fluorescence microscopy 
images, the green fluorescence representing recombinant GFP-PvICPc was found 
localized in the cytoplasm of transfected HepG2 cells (Figure 4.22). 
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   (A)         (B)
Figure 4.21 DNA sequences encoding PvICPc were subcloned into pXJ40
Gel visualization was performed to evaluate (A) the PCR amplification of PvICPc 
from pCR-Blunt-II-TOPO/PvICP and (B) the restriction digestion of pXJ40/PvICPc 
recombinant vector construct using restriction enzymes BamHI and SalI. (A) The 
amplified PvICPc product was represented by  a prominent band of approximately 
472bp. (B) The positive construct of pXJ40/PvICPc recombinant  vector was indicated 
by representative bands of pXJ40-GFP and PvICPc. Legend: M, DNA marker.
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4.4.2 Presence of PvICPc protects HepG2 cells from tBHP-induced apoptosis
 To set up the cell death assay, the optimal concentration of tBHP required to 
induce apoptosis in HepG2 cells was first evaluated. Cells cultivated in 24-well plates 
were allowed to reach approximately 90% confluency  before being treated with 
various concentrations of tBHP for four hours at 37°C and 5% CO2. After treatment, 
TMRE and Hoechst 33258 were used to stain and identify viable and dying cells. 
TMRE only stains mitochondria with intact membrane potential in viable cells, and 
Hoechst 33258 facilitates the visualization of chromatin condensation in dying cells. 
Therefore, dying cells are identified as those with an absence of TMRE but intensified 
Hoechst 33258 staining, and vice versa for viable cells (Figure 4.23). Analysis 
performed using the fluorescence microscope revealed that treatment with ≥100 mM 
tBHP-induced loss of TMRE and intensified Hoechst 33258 staining in ≥80% of the 
treated cells. This suggested that at least 100 mM tBHP was required to induce cell 
death in the treated cells. However, it was also noted that treatment with ≥150 mM 
tBHP-induced the treated cells to leak their cellular content during incubation which 
was indicative of necrotic cell death. This suggested that  concentrations of tBHP ≥150 
mM were unsuitable for the cell death assay, and thus 100 mM tBHP was used to treat 




Figure 4.23 Evaluating the concentration of tBHP required to induce apoptosis in 
HepG2 cells
HepG2 cells were treated with various concentrations of tBHP, A – 70nM; B - 35µM; 
C - 70µM; D – 100 µM; E - 150µM; F - 200µM  and G - 300µM  for 4 hours. After 
treatment, TMRE was used to stain intact mitochondria and DNA condensation was 
visualized by Hoechst 33258 staining. Viable cells exhibited TMRE staining (red) and 
dull Hoechst  33258 staining (blue). Absence of TMRE staining and intensified 
Hoechst 33258 staining were indicative of a dying cell. White and red arrows indicate 
examples of viable and dying cells, respectively. The white bars represent 200µm.
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 To evaluate if the heterologous expression of recombinant PvICPc in HepG2 
renders any protection against tBHP-induced cell death, HepG2 cells expressing either 
GFP-PvICPc or GFP recombinant proteins were treated with 100 mM  tBHP for four 
hours. Following this, the cells were treated with TMRE and Hoechst 33258 stains to 
visualize and identify  dying cells. As indicated in Figure 4.24, 10.3% of the HepG2 
cells expressing GFP-PvICPc were observed to have lost their mitochondria 
membrane potential and displayed signs of chromatin condensation at the end of 4 
hours incubation. In contrast, 47.8% of the control cells expressing GFP were found to 
possess depolarized mitochondria and condensed chromatin (Figure 4.24). This 






Figure 4.24 Percentage of dying cells in tBHP-induced cell death assay
(A) HepG2 cells transfected with pXJ40 or pXJ40/PvICPc were visualized using a 
fluorescence microscope 4 - 7 hours after treatment with 100 µM tBHP. Viable cells 
(white arrow) that possess intact mitochondria membrane potential are stained red by 
TMRE. In contrast, dying cells (red arrow) exhibit a loss of the mitochondria 
membrane potential, indicated by  absence of TMRE staining, and condensed 
chromatin, indicated by intensified Hoechst 33258 staining (blue). (B) Green 
fluorescent HepG2 cells were counted and the average percentage of dying cells were 
presented. HepG2 cells expressing GFP-PvICPc exhibited better survival rates with 
only 10.3 % dying cells as compared to that of cells expressing GFP, i.e. 47.8%. The ± 
standard deviations are represented by the error bars. *P value of <0.01 between GFP 
and GFP-PvICPc expressing HepG2 cells using Student T-test. The white bars in (A) 
represents 100 µm.
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4.4.3 PvICPc did not inhibit the activities of human caspases in vitro
 To investigate if PvICPc may  facilitate this process through the inhibition of 
human caspases, its inhibitory activity  against human caspases 1 to 10 was tested 
using fluorometric assays. Consistent with results reported by Hansen et al. (2011), 
PvICPc did not exhibit any significant activity  against human caspases 3 and 8 (Figure 
4.25). When the inhibitory activity of PvICPc was further evaluated with the other 8 
caspases, no significant reduction in proteolytic activities was observed (Figure 4.25). 
This suggested that the human caspases are unlikely targets of PvICPc during the 
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4.4.4 PvICPc selectively inhibits human cathepsins in vitro
 Human cathepsins can promote cellular apoptosis via a mitochondria-
dependent pathway (Figure 2.6). In addition, they  are known to mediate other host 
defense mechanisms that can attenuate the development of Plasmodium parasites 
inside the human. Hence, inhibition of these exogenous proteases by plasmodial ICPs 
has been proposed to promote parasite survival (Pandey  et  al., 2006; Pei et  al., 2013; 
Rennenberg et al., 2010). To evaluate the potential targets of PvICPc, the proteolytic 
activities of human cathepsins B, L and S were investigated in the presence of MBP-
PvICPc-His6 using fluorometric assays. Increasing concentrations of MBP-PvICPc-
His6 led to a decrease in cathepsin L and cathepsin S proteolytic activities against Z-
Phe-Arg-AMC and Z-Val-Val-Arg-AMC substrates, respectively (Figure 4.26). 
However, MBP-PvICPc-His6 did not exhibit any significant inhibitory activity against 
cathepsin B (Figure 4.26).  
 The lack of PvICPc inhibitory activity against cathepsin B is likely to be a 
result of steric clashes between PvICPc and cathepsin B. Unlike cathepsins L and S, 
cathepsin B possesses both endopeptidase and exopeptidase activities. The additional 
exopeptidase activity  is conferred by the presence of an occluding loop at  the active 
site (Turk et al., 2012). 3D model analysis of modeled PvICPc superimposed onto the 
chagasin:cathepsin B protein complex template (PDB ID: 3CBJ) revealed potential 
steric clashes between the L0 and L6 of PvICPc with the occluding loop of cathepsin 
B (Figure 4.27). These steric clashes are likely to prevent interaction from occurring 
between the inhibitor and protease proteins, hence accounting for the inability  of 
MBP-PvICPc-His6 to inhibit cathepsin B in vitro. The lack of inhibitory activity 
against human cathepsin B by plasmodial ICP was proposed to indirectly  facilitate 
parasite egress towards the end of exoerythrocytic development (Hansen et al., 2011).  
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Figure 4.26 Recombinant PvICPc inhibited the proteolytic activity of cathepsins 
L and S but not cathepsin B
The proteolytic activity of human cathepsins B, L and S were evaluated with or 
without MBP-PvICPc-His6 under appropriate pH conditions using fluorometric 
assays. The cathepsin activities in the absence of MBP-PvICPc-His6 protein were 
considered as 100% and the percentage of residual activity in the presence of 
increasing concentrations of MBP-PvICPc-His6 was calculated. The proteolytic 
activity of cathepsin B was additionally evaluated in the presence of 5 µM 
recombinant PvICPc. The ± standard deviations are represented by the error bars.
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Figure 4.27 3D modeling of protein:protein interaction between PvICPc and 
human cathepsin B
The modeled 3D structures of PvICPc were superimposed onto the chagasin:cathepsin 
B protein complex template (PDB ID: 3CBJ; Redzynia et al. 2006). The steric clashes 
was predicted between the L0 and L6 loops of PvICPc with the occluding loop  of 
cathepsin B. Human cathepsin B is coloured green and PvICPc is coloured blue.
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4.4.5 PvICPc is a potential inhibitor of host cell apoptosis during the 
exoerythrocytic stages
 During the exoerythrocytic stages, Plasmodium parasites were found to 
subvert the apoptosis mechanism of infected hepatocytes (van de Sand et al., 2005). 
Interestingly, expression of PbICPc in HepG2 cell cytoplasm was demonstrated to be 
sufficient for inhibiting parasite-independent cell death despite its lack of ability to 
suppress the activities of human caspases 3 and 8 in vitro (Hansen et al., 2011; 
Rennenberg et  al., 2010). In this study, the presence of PvICPc in HepG2 cell 
cytoplasm was similarly found to confer protection against tBHP-induced cell death 
(Figure 4.24). Likewise, PvICPc did not exhibit any  inhibitory activity against human 
caspases 3 and 8, nor any of the other 8 caspases tested (Figure 4.25). However, 
recombinant PvICPc was able to inhibit the proteolytic activities of human cathepsins 
L and S, suggesting that suppression of host cell apoptosis may  implicate cathepsin 
inhibition in vivo. 
 Treatment with tBHP has been reported to cause lysosomal membrane 
destabilization, and in turn, the release of lysosomal cathepsins (Miura et al., 2010). 
After being released into the cell cytoplasm, lysosomal cathepsins can promote 
apoptotic signaling through the processing of pro-apoptotic and anti-apoptotic proteins 
(Figure 2.6) (Repnik et al., 2012). Inhibition of their proteolytic activities by PvICPc 
would thus help to suppress the initiation of cellular apoptosis. However, results 
obtained here and previous studies suggest that some lysosomal cathepsins, such as 
cathepsin B, are unlikely  targets of plasmodial ICPs in vivo. Hence, the suppression of 
host cell apoptosis by PvICPc may be a complicated process that implicate other 
unknown proteins. To decipher the mechanism of this process, it would be useful to 
identify interacting partners of PvICPc in the hepatocyte cytoplasm. The co-
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immunoprecipitation assay could be adopted to isolate the interacting partners of 
PvICPc from the hepatocyte cell lysate. Following this, the identities of the isolated 
proteins could be determined by mass spectrometric analysis. Results obtained from 
these studies would fill the knowledge gaps on the function of plasmodial ICP in 
human host cells. 
 While it remains unclear how plasmodial ICPs may  facilitate the suppression 
of host cell apoptosis, findings presented here suggest that ICP from P. vivax, the 
human malaria parasite, possesses a similar ability as that reported in the murine 
model (Rennenberg et al., 2010). This ability may  not only be useful during 
exoerythrocytic development of P. vivax, but perhaps also during its dormant stage to 
protect the hypnozoites hidden within the infected hepatocyte from normal hepatocyte 
turnover.
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4.4.6 Potential implications of host cell apoptosis during parasite egress
 Early in the exoerythrocytic stage, subversion of hepatocyte apoptosis 
promotes the development of P. berghei (van de Sand et al., 2005). However, towards 
the end of the exoerythrocytic stage, the situation changes and hepatocytes are 
induced to undergo apoptosis. Distinct features of apoptosis, i.e. condensation of cell 
nucleus and depolarization of mitochondria membrane potential, were observed in the 
host cell (Sturm et al., 2006). In addition, blebbing of the dying cell occurred but the 
resultant vesicles were filled with the P. berghei merozoites that budded off into the 
sinusoid lumen without being phagocytosed by  neighbouring or resident Küpffer cells. 
Surprisingly, the activation of human caspase signaling pathway and switching of the 
phosphoserine to the outer leaflet of the cell membrane were also not  detected. These 
peculiarities led the authors to suggest that P. berghei induced an unusual form of cell 
death in the host cell during egress. 
 Currently, the mechanism by which P. berghei coordinates this unusual form of 
cell death in the infected hepatocytes remains elusive. Interestingly, metacaspases 
(MCAs), caspase-like proteases, have been identified in P. berghei, P. falciparum and 
P. vivax (Le Chat et al., 2007; Rezanezhad et al., 2011; Wu et al., 2003). While the 
role of P. berghei and P. vivax MCAs in apoptosis has not been reported, heterologous 
expression of P. falciparum MCA in yeast cells was found to induce apoptotic features 
under oxidative stress (Meslin et al., 2011). This finding suggested that MCA may 
possess similar functional roles as human caspases to mediate apoptosis (Meslin et al., 
2011). Moreover, the crisis form of P. falciparum that resembles general features of 
mammalian apoptosis has been reported, suggesting that the parasite possesses the 
necessary  apoptosis mechanism (Ch'ng et al., 2010; Meslin et al., 2007). While it 
remains unclear why the unicellular Plasmodium parasite may undergo apoptosis, the 
115
export of plasmodial MCAs into the hepatocyte cytoplasm during exoerythrocytic 
egress may be more apparent. Presence of plasmodial MCA may act to substitute the 
functions of human caspases to induce apoptosis in the hepatocytes, enabling the 
parasite to generate apoptosis features without activating the host caspases. Utilization 
of plasmodial enzymes may offer the parasite a better control over the process rather 
than relying on the host apoptotic machinery that inherently possesses different goals 
from the parasite. Hence, it  appears that suppression of host cell apoptosis by 
plasmodial ICP helps to set up the conditions required for the parasite to induce this 
unusual form of cell death. Considering this intriguing potential, it  may be worthy to 
further investigate the expression and localization profiles of plasmodial MCAs to 
gather more insights on how the parasites may  coordinate its egress from the infected 
hepatocytes. 
 PbICP was reportedly  released into the cell cytoplasm during parasite egress 
(Rennenberg et  al., 2010). Its inhibitory profile thus offered some clues on the 
possible identity  of these proteases. Consequently, serine rich antigen (SERA) 
proteases and cathepsin B-like proteases were proposed as potential mediators of this 
process. SERA proteases were found to be released along with PbICP during egress 
and they have been reported to mediate the egress of Plasmodium parasites during the 
erythrocyte stage (Putrianti et  al., 2010). Although these proteases possess a papain-
like mature domain, 3D modeling analysis revealed that they are unlikely targets of 
PbICP inhibition due to steric clashes at the active sites (Hansen et al., 2011). Hence, 
further biochemical assays are required to validate this postulation.
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4.4.7 Inhibition of human cathepsins may disrupt host defense mechanisms
 Previous studies of plasmodial ICPs suggested that its secretion may promote 
the survival and propagation of the Plasmodium parasites through the inhibition of 
extracellular cysteine proteases such as cathepsin L (Pandey  et al., 2006; Pei et al., 
2013; Rennenberg et al., 2010). Although the secretion of PvICP by P. vivax was not 
investigated in this study, the presence of a putative N-terminal signal peptide alludes 
to its possible secretion by the parasite. Moreover, recombinant PvICPc was found to 
inhibit the proteolytic activities of human cathepsins L and S (Figure 4.26), suggesting 
a potential role outside the P. vivax parasite. Cathepsins L and S are important 
enzymes that  mediate antigen processing and presentation in antigen-presenting cells 
(APCs) (Hsing and Rudensky, 2005; Santamaria et al., 1998). To disrupt this 
immunological process, some parasitic nematodes have been found to express 
cystatins that inhibit cathepsins L and S (Kotsyfakis et al., 2006; Manoury  et al., 2001; 
Murray et al., 2005; Sa-Nunes et al., 2009; Schnoeller et al., 2008). Since such 
disruption is potentially  beneficial for the survival of P. vivax parasite, it is possible 
that PvICPc may play a similar role during Plasmodium infection. Hence, further 
studies performed to investigate the influence of PvICPc on APCs may provide 
information about its potential role in inhibiting immune responses against the 
invading P. vivax parasite.
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Conclusion and Future Directions
 Cysteine proteases from both the Plasmodium parasites and human host 
facilitate diverse biological processes that  can either promote or attenuate parasite 
development. In order to survive, the parasite needs to keep its proteolytic activities in 
check, i.e. allowing those that are pro-parasite to proceed while inhibiting others that 
are deleterious. In humans, regulation of papain-like cysteine proteases is mediated by 
a family of protein inhibitors known as cystatins (Turk et al., 2012). These inhibitors 
have been extensively studied and are known to possess well-defined physiological 
roles. In contrast, information on the regulation of cysteine proteases by the 
Plasmodium parasites has only begun to surface within the last decade following the 
discovery  of PfICP (Pandey  et al., 2006). Thus far, only a single copy  of ICP has been 
reported in P. berghei and P. yoelii. Attempts to produce ICP knockout in P. berghei 
and P. yoelii parasites have been consistently unsuccessful, accentuating their 
importance in the Plasmodium parasites. Indeed, plasmodial ICPs were found to be 
essential for host cell invasion by the Plasmodium parasite during both the 
exoerythrocytic and erythrocytic stages. Furthermore, they are likely to play an 
important role in protecting the parasite from host defense mechanisms and unspecific 
protease activities through the inhibition of both endogenous and exogenous cysteine 
proteases. In this project, investigation on plasmodial ICP was performed to gain 
insights on its presence and functionality  in P. vivax. Biochemical and functional 
assays were carried out with the aim of uncovering its potential roles in P. vivax and 
the human host. 
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5.1 Reporting a functional PvICP encoded in the genome of P. vivax
 Plasmodial ICPs mediate important  biological processes during the 
development of Plasmodium parasite in the mammalian hosts (Figure 2.8). However, 
prior to this project, the presence of a corresponding homologue in P. vivax had not 
been reported, and it was not known how the parasite may  counter undesirable 
cysteine protease activities. To shed light in this unexplored area of P. vivax biology, 
this study  begun with an in silico approach and uncovered a putative PvICP. The 
putative protein was found to harbor a cysteine protease inhibitor domain at its C-
terminus, PvICPc, and further structural analysis revealed conserved features that 
were suggestive of its functionality. Acting on this information, PvICPc was 
subsequently cloned and heterologously  expressed in E. coli. The resultant 
recombinant protein was found to be functionally active and it inhibited the 
proteolytic activity  of papain in vitro. The inhibitory activity of PvICPc was 
subsequently  evaluated against both endogenous and exogenous cysteine proteases. 
The identification of a functional PvICP marks a small step forward in our 
understanding about cysteine protease regulation in P. vivax.
5.2 PvICP is a potential inhibitor of vivapain 4 in P. vivax
 Current evidence suggests that plasmodial ICPs interact with endogenous 
cysteine protease haemoglobinases to inhibit their proteolytic activities in vivo. To 
evaluate if PvICP may function as an endogenous cysteine protease inhibitor in P. 
vivax, heterologous expression of the cysteine protease, Vx4, was first performed to 
obtain recombinant proteins for subsequent biochemical characterization assays. 
Although expression protocols that entailed the refolding of insoluble plasmodial 
cysteine protease haemoglobinases were commonly used in other studies, an 
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alternative approach was successfully  adopted here. Vx4 was solubly expressed as an 
active fusion protein and a dual-tagged purification strategy was established to obtain 
purer samples of mature Vx4. Using the purified recombinant proteins, PvICPc was 
found to inhibit the autocleavage and haemoglobinase activities of Vx4 in vitro. These 
findings suggested that PvICPc possesses intracellular roles in preventing undesired 
Vx4 protease activity  in the parasite cytoplasm and/or regulate the activation of Vx4 
zymogen (Figure 5.1). 
5.3 PvICPc may protect P. vivax against cathepsin-mediated host defense 
mechanisms  
 Plasmodium parasites hiding in the host cells are protected from the host 
immune system, but they  still face the threat of elimination when the host cells 
undergo apoptosis (Heussler et al., 2001; Rennenberg et al., 2010). Hence, 
mechanisms that can subvert  this process are important to ensure parasite survival in 
the infected host. In this study, heterologous expression of PvICPc in HepG2 cells was 
shown to protect the host cells from chemically induced apoptosis. Although the 
mechanism by which this process is mediated remains unclear, the inhibitory profile 
of PvICPc obtained here suggest that it is likely to occur independent of direct caspase 
inhibition by PvICPc. In contrast, the inhibition of human cathepsins by PvICPc may 
be crucial since these proteases can tilt the balance of cellular pro-apoptosis and anti-
apoptotic proteins to initiate apoptosis (Figure 2.4). Collectively, these findings 
suggest that PvICPc may  represent an important mechanism in P. vivax that disrupts 
host cell apoptosis to protect itself during development or dormancy (Figure 5.1).
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Figure 5.1 Proposed roles of PvICPc in P. vivax life cycle
This figure was drawn to correlate the inhibitory profile of PvICPc, derived in this 
study, with its potential sites of actions and putative physiological roles in P. vivax. 
Inhibition of different cysteine proteases by PvICPc and their consequences are 
illustrated around the circumference of the figure and assigned with unique roman 
numerals highlighted in yellow. The roman numerals were marked at different stages 
of the parasite cell cycle (center of the figure) to depict the potential sites of PvICPc 
actions.
(i & ii) PvICPc may disrupt human cathepsins that mediate host defense 
mechanisms
Human cathepsins released by the human host cells can proteolytically attack P. vivax 
to eliminate its host  system. Inhibition of these proteases would hence protect the 
parasite and promote its survival.
(iii) PvICPc may inhibit human cathepsins to prevent the initiation of apoptosis 
in the infected hepatocytes
Cathepsins can promote apoptosis through the processing of both anti-apoptotic and 
pro-apoptotic proteins. Suppressing their proteolytic activities by PvICPc may thus 
help  to disrupt this undesirable process against the developing P. vivax. Furthermore, 
it may prevent the elimination of hypnozoites during the natural turnover of infected 
hepatocytes.  
(iv) PvICPc may hinder human immunological responses
During migration or rupture of infected host cells, antigens released are taken up by 
APCs. PvICPc may  inhibit human cathepsins L and S to hinder MHC II antigen 
presentation, and hence slow the onset of immune responses against  parasite. This 
may allow more time for the P. vivax to locate and invade suitable host cells which 
can then shield it from the undesirable effects of human immune responses.
(v) Activation of Vx4 zymogen may be regulated by PvICPc 
(vi and vii) PvICPc localized in parasite cytoplasm may function to protect 
parasite from unspecific Vx4 activities
Legend: - plasmodial ICP; CTS  - human cathepsins; CSP - caspases; - initiator 
caspases; - executioner caspases; - shed plasmodial proteins;  - cathepsin 
processed antigens; Y - antibodies;  - cytokines; - Vx4 zymogen; - activated 
Vx4; Mr - merosomes; dotted lines indicate the biological processes that may  be 




 Currently, primaquine is the only  available treatment against the relapse of P. 
vivax malaria. Considering the problems associated with its use (Section 2.3), there is 
thus a need to identify  new strategies that  can attenuate P. vivax at the exoerythrocytic 
stages. Interestingly, volunteers immunized with irradiated P. falciparum sporozoite 
vaccine were found to elicit antisera against PfICP (Aguiar J, 2009). PyICP was 
subsequently  shown to be a potential vaccine candidate for pre-erythrocytic malaria 
using the murine malaria model (Limbach et al., 2011). Consistent with these findings, 
treatment with anti-PfICP and anti-PbICP antibodies was demonstrated to prevent host 
cell invasion in vitro by  the P. falciparum merozoites and P. berghei sporozoites, 
respectively (Pandey et al., 2006; Rennenberg et al., 2010). 
 Following the identification of PvICP, it is tempting to question if developing 
human immune responses against PvICP may similarly prevent migration of P. vivax 
sporozoites and merozoites invasions and in turn, relapse of P. vivax malaria. 
Furthermore, it  is not known if PvICPc assumes similar physiological roles as other 
plasmodial ICPs, reported previously. Hence, further studies to investigate the 
expression and localization profiles of PvICP during the life cycle of P. vivax may 
yield valuable information on its functional roles in vivo. To facilitate the 
investigation, recombinant PvICPc can used to raise PvICPc-specific antibodies for 
localization studies and functional assays. Since protocols for continual P. vivax 
parasite culture are currently inaccessible for most researchers, it is anticipated that 
these investigations would require an ex vivo approach using parasites from field 
isolates (Russell et al., 2012). Although obtaining these samples may be challenging, 
information obtained through this approach is arguably more representative of the 
Plasmodium parasites in a clinical setting (Russell et al., 2012).
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 PvICPc has also been demonstrated to exhibit inhibitory activity  against 
important human cathepsins, i.e. cathepsins L and S, that are essential in MHC II 
antigen presentation. Disruption of these proteases may consequently hinder the 
elicitation of human immune responses. Furthermore, human cathepsins are known to 
mediate autophagy, a cellular process reported to defend against intracellular 
pathogens (Faure and Lafont, 2013; Kaminskyy and Zhivotovsky, 2012). Hence, it 
would interesting to investigate whether a similar defense mechanism, i.e. autophagy, 
is stimulated during Plasmodium infection. Nonetheless, it  may be worthy to further 
evaluate its inhibitory activity against MHC II antigen presentation in human APCs, 




 P. vivax continues to threaten billions of people every  year with relapsing 
malaria. Although it  causes less fatalities than P. falciparum, P. vivax has proven to be 
more challenging to control and treat due to its ability to form hypnozoites (Shanks, 
2012). Past inattention in the area of P. vivax malaria research has limited our 
understanding about its biological processes, and consequently hindered efforts to 
develop new strategies against it  (Mueller et al., 2009). This is exacerbated by smaller 
research fund allocations and the continual absence of accessible techniques for P. 
vivax parasite culture. In light of these issues, in vitro and ex vivo approaches are 
likely to remain important avenues for investigating the enigmatic biology of P. vivax 
(Russell et al., 2012). Additional information obtained would facilitate the discovery 
of new drug targets and consequently novel strategies to overcome the problems of 
controlling transmission and relapse of P. vivax.
 Regulation of cysteine protease is a fundamental cellular process in P. vivax. In 
the human host, cystatins are known to play pivotal roles inhibiting inappropriate 
human cathepsin activities (Turk et al., 2012). However, the corresponding 
homologues are apparently absent in P. vivax suggesting mechanistic differences in 
the regulation of cysteine proteases between the parasite and human host. Indeed, 
analysis of PvICP, uncovered in this study, revealed differences in both structural and 
inhibitory properties between the human and parasite inhibitors. Deciphering this 
different mode of cysteine protease regulation in P. vivax is therefore important as it 
may potentially reveal clues for the development of new strategies against P. vivax. 
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